US20200179668A1 - Microdevice and method for transdermal delivery and sampling of active substances - Google Patents
Microdevice and method for transdermal delivery and sampling of active substances Download PDFInfo
- Publication number
- US20200179668A1 US20200179668A1 US16/735,160 US202016735160A US2020179668A1 US 20200179668 A1 US20200179668 A1 US 20200179668A1 US 202016735160 A US202016735160 A US 202016735160A US 2020179668 A1 US2020179668 A1 US 2020179668A1
- Authority
- US
- United States
- Prior art keywords
- skin
- agent
- kit
- microdevice
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title abstract description 45
- 239000013543 active substance Substances 0.000 title description 26
- 230000037317 transdermal delivery Effects 0.000 title description 14
- 238000005070 sampling Methods 0.000 title description 2
- 210000003491 skin Anatomy 0.000 claims description 163
- 239000003795 chemical substances by application Substances 0.000 claims description 99
- 239000000203 mixture Substances 0.000 claims description 57
- 239000002502 liposome Substances 0.000 claims description 46
- 238000009472 formulation Methods 0.000 claims description 43
- 208000002193 Pain Diseases 0.000 claims description 35
- 230000036407 pain Effects 0.000 claims description 33
- 210000000434 stratum corneum Anatomy 0.000 claims description 32
- 241000124008 Mammalia Species 0.000 claims description 24
- 239000002105 nanoparticle Substances 0.000 claims description 19
- 229960005486 vaccine Drugs 0.000 claims description 19
- 230000000699 topical effect Effects 0.000 claims description 14
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical group CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 11
- 239000007933 dermal patch Substances 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 11
- 230000007246 mechanism Effects 0.000 claims description 11
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 10
- 229960003668 docetaxel Drugs 0.000 claims description 10
- 206010022000 influenza Diseases 0.000 claims description 9
- 239000006210 lotion Substances 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 238000012385 systemic delivery Methods 0.000 claims description 8
- 238000002604 ultrasonography Methods 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 229960004194 lidocaine Drugs 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 239000012867 bioactive agent Substances 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 5
- 229960002372 tetracaine Drugs 0.000 claims description 5
- 241000193738 Bacillus anthracis Species 0.000 claims description 4
- 201000006082 Chickenpox Diseases 0.000 claims description 4
- 206010008631 Cholera Diseases 0.000 claims description 4
- 241000606768 Haemophilus influenzae Species 0.000 claims description 4
- 201000005505 Measles Diseases 0.000 claims description 4
- 208000005647 Mumps Diseases 0.000 claims description 4
- 201000005702 Pertussis Diseases 0.000 claims description 4
- 208000000474 Poliomyelitis Diseases 0.000 claims description 4
- 206010037742 Rabies Diseases 0.000 claims description 4
- 206010043376 Tetanus Diseases 0.000 claims description 4
- 206010046980 Varicella Diseases 0.000 claims description 4
- 208000003152 Yellow Fever Diseases 0.000 claims description 4
- 206010013023 diphtheria Diseases 0.000 claims description 4
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 208000010805 mumps infectious disease Diseases 0.000 claims description 4
- 201000005404 rubella Diseases 0.000 claims description 4
- 201000008827 tuberculosis Diseases 0.000 claims description 4
- 108010041986 DNA Vaccines Proteins 0.000 claims description 3
- 229940021995 DNA vaccine Drugs 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000385 dyclonine Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229940023041 peptide vaccine Drugs 0.000 claims description 2
- 229940023143 protein vaccine Drugs 0.000 claims description 2
- 229940126577 synthetic vaccine Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 65
- 229940079593 drug Drugs 0.000 description 59
- 238000012384 transportation and delivery Methods 0.000 description 33
- 239000000126 substance Substances 0.000 description 18
- 230000035515 penetration Effects 0.000 description 17
- 239000002537 cosmetic Substances 0.000 description 14
- 238000012377 drug delivery Methods 0.000 description 14
- 239000002090 nanochannel Substances 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000007726 management method Methods 0.000 description 12
- 102000014150 Interferons Human genes 0.000 description 10
- 108010050904 Interferons Proteins 0.000 description 10
- 229940079322 interferon Drugs 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 230000004888 barrier function Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 230000008591 skin barrier function Effects 0.000 description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 7
- 229920002674 hyaluronan Polymers 0.000 description 7
- 229960003160 hyaluronic acid Drugs 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 6
- 229940094657 botulinum toxin type a Drugs 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 150000002605 large molecules Chemical class 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 230000036572 transepidermal water loss Effects 0.000 description 6
- -1 vaccines Substances 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000013271 transdermal drug delivery Methods 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 229960005188 collagen Drugs 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229940019097 EMLA Drugs 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 238000012382 advanced drug delivery Methods 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 229940061720 alpha hydroxy acid Drugs 0.000 description 3
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229940035363 muscle relaxants Drugs 0.000 description 3
- 239000003158 myorelaxant agent Substances 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- QNLDTXPVZPRSAM-UHFFFAOYSA-N 17146-95-1 Chemical compound CC(O)C(O)=O.C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 QNLDTXPVZPRSAM-UHFFFAOYSA-N 0.000 description 2
- TVYLLZQTGLZFBW-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol Chemical compound COC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 2
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 2
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940110331 bextra Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 229940047495 celebrex Drugs 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000009713 electroplating Methods 0.000 description 2
- 238000004049 embossing Methods 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001097 facial muscle Anatomy 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 102000058004 human PTH Human genes 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
- 229960001410 hydromorphone Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000001459 lithography Methods 0.000 description 2
- 238000003754 machining Methods 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 229940065778 narcan Drugs 0.000 description 2
- 239000000014 opioid analgesic Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 229960001807 prilocaine Drugs 0.000 description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960004739 sufentanil Drugs 0.000 description 2
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940066690 talwin Drugs 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 238000000427 thin-film deposition Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- 229960003107 tramadol hydrochloride Drugs 0.000 description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 229940054370 ultram Drugs 0.000 description 2
- 229960002004 valdecoxib Drugs 0.000 description 2
- VKDGNNYJFSHYKD-UHFFFAOYSA-N 2,5-diamino-2-(difluoromethyl)pentanoic acid;hydron;chloride Chemical compound Cl.NCCCC(N)(C(F)F)C(O)=O VKDGNNYJFSHYKD-UHFFFAOYSA-N 0.000 description 1
- GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 238000009623 Bosch process Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical compound CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000036621 balding Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 description 1
- 229960004587 carisoprodol Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 description 1
- 229960003633 chlorzoxazone Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960002046 eflornithine hydrochloride Drugs 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000013266 extended drug release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- UGKDIUIOSMUOAW-UHFFFAOYSA-N iron nickel Chemical compound [Fe].[Ni] UGKDIUIOSMUOAW-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 229940060977 lidoderm Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229960000509 metaxalone Drugs 0.000 description 1
- 229960002330 methocarbamol Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910021421 monocrystalline silicon Inorganic materials 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940098893 novolin r Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920006260 polyaryletherketone Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005596 polymer binder Polymers 0.000 description 1
- 239000002491 polymer binding agent Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910021426 porous silicon Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229940095694 transdermal product Drugs 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/003—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a lumen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y02A50/387—
-
- Y02A50/465—
Definitions
- the present application relates to a microdevice for transdermal delivery of an active substance and methods of using the same.
- Transdermal Drug Delivery Systems can also deliver drugs at a steady rate to achieve a sustainable release, which is an additional advantage.
- transdermal drug delivery methods have their drawbacks. Most important is the fact that conventional transdermal system (TTS) technology is only suited for delivering relatively small drugs across the skin. It also suffers from slow onset, because of the outer skin barrier layer, stratum corneum, that limits the through skin drug transport.
- New transdermal drug delivery methods are therefore required to drive future growth in transdermal product markets.
- Biological products would also profit greatly from new, non-invasive delivery technology to replace hypodermic needle injection that is the current standard.
- the original players in the transdermal field failed to introduce such improvements, which were then introduced by a number of innovator companies.
- the device/drug combination includes, but is not limited to any one or more of the following: (1) pre-treating the mammal using the device, then applying the drug to the mammal; (2) applying the drug to the mammal, then treating the mammal with the device; (3) temporarily anchoring the drug onto the device, then treating the mammal with the device/drug system.
- the method of delivering an agent described herein includes: (1) applying an applicator to a microdevice to cause the microdevice to contact an area of skin of a mammal (e.g., patient) to generate a prepared area of skin comprising a plurality of nanopores or nanochannels through the stratum corneum in a defined area of skin, (2) applying a wet formulation comprising the agent to the area of skin being prepared either before or after the microdevice has generated the plurality of nanopores or nanochannels in the prepared area of skin, (3) applying an occlusive layer over the agent and directly on the prepared area of skin such that the occlusive layer prevents air from coming into contact with the prepared area of skin following the removal of the applicator and microdevice from the skin, and (4) causing an effective amount of an agent to deliver to the patient through the nanopores or nanochannels in the stratum corneum.
- the microstructure can be coated with a composition comprising the agent.
- the causing is by applying a wet formulation including liposome nanoparticles encapsulating the agent and causing the agent to transport through the stratum corneum into the mammal.
- the present subject matter provides an applicator of the microdevice described herein.
- FIGS. 1A and 1B show two preparations of liposome nanoparticles containing docetaxel.
- FIG. 2 shows penetration (%) of docetaxel in elastic liposomes with or without microneedle and with or without an occlusive layer.
- FIG. 3 shows fluorescence labeled docetaxel encapsulated within elastic liposome nanoparticles being successfully transported through skin.
- FIG. 4 shows delivery of interferon via different methods.
- FIG. 5 shows delivery of interferon with a dry formulation.
- FIG. 6 shows a graph of Trans-Epidermal Water Loss with or without microneedle application.
- FIG. 7 shows a graph of serum insulation concentration with an occlusive layer applied.
- the present subject matter provides high-aspect-ratio microstructures (HARMS) and methods of using the same.
- the present subject matter also provides methods of using the device for transdermal delivery of drugs, vaccines, diagnostic agents and cosmetic substances and sampling of body fluids for treating, preventing, or ameliorating a medical condition of a mammal such as a human being.
- the method comprises treating a topical site of a mammal using a device, and applying an effective amount of an agent to the topical site to allow the agent to penetrate into the body of the mammal.
- the device can include an array of microstructures.
- the microstructure can have an aspect ratio of about 5:1, 10:1, 15:1, 20:1 or higher.
- the present subject matter provides a system for topical or systemic delivery of an agent for a medical condition in a mammal (e.g., a patient).
- the system comprises: (1) a microdevice comprising an array of microstructures, (2) an applicator for applying the microdevice to an area of skin of a patient to generate a prepared area of skin comprising a plurality of nanopores or nanochannels in stratum corneum of the prepared area of skin, and (3) a delivery mechanism for causing the agent to be delivered to the mammal through the nanopores or nanochannels in the stratum corneum of the prepared area of skin.
- the microdevice can comprise nanoscale tips and microscale body that can have an aspect ratio of about 5:1, 10:1, 15:1, 20:1 or higher.
- the present subject matter provides a method of delivering an agent for a medical condition to a mammal.
- the method comprises: (1) applying an applicator to a microdevice to cause the microdevice to contact an area of skin to generate a prepared area of skin comprising a plurality of nanopores or nanochannels through the stratum corneum of the area of skin, (2) applying a composition comprising the agent to the prepared area of skin, (3) applying an occlusive layer over the area of skin, and (4) causing an effective amount of the agent to deliver to the patient through the nanopores or nanochannels in the stratum corneum.
- the method of delivering an agent described herein includes: (1) applying a composition comprising the agent to an area of skin, (2) applying an applicator to a microdevice to cause the microdevice to contact the area of skin to generate a plurality of nanopores or nanochannels through the stratum corneum of the area of skin, (3) applying an occlusive layer over the area of skin, and (4) causing an effective amount of the agent to deliver to the patient through the nanopores or nanochannels in the stratum corneum.
- the method of delivering an agent described herein includes: (1) applying an applicator to a microdevice to cause the microdevice to contact an area of skin of a mammal (e.g., patient) to generate a prepared area of skin comprising a plurality of nanopores or nanochannels through the stratum corneum of the area of skin, (2) applying an occlusive layer over the area of skin, and (3) causing an effective amount of an agent to deliver to the patient through the nanopores or nanochannels in the stratum corneum.
- the microdevice can be coated with a composition comprising the agent.
- the causing is by applying a wet formulation including elastic liposomes comprising liposome nanoparticles encapsulating the agent and causing the agent to transport through the stratum corneum into the mammal.
- the wet formulation does not include elastic liposomes.
- a wet formulation refers to any form of wet formulation.
- a wet formulation can be a skin patch, cream, ointment, or lotion.
- the wet formulation can include elastic liposomes comprising liposome nanoparticles encapsulating an agent.
- the wet formulation can include an agent, but not elastic liposomes.
- agent refers to any diagnostic, therapeutic, or preventive agents.
- agent is sometimes interchangeably referred to as “active agent,” “bioactive agent,” or “active substance.”
- Skin has a biological barrier called stratum corneum in its outer layer. This layer of about 10-25 microns thick prevents most of the molecules from penetrating through the skin.
- the layer below the stratum corneum is called viable epidermis.
- Epidermis is between 50 to 100 micron thick.
- the viable epidermis layer has no blood vessels and the molecules in this layer can be transported to and from the dermis, a layer under the viable epidermis, which is between 1 to 3 mm thick.
- a skin patch is only able to deliver drug molecules of less than 500 Da. In addition, these small molecules are typically limited to hydrophobic ones.
- the microdevice described herein can be used for effective transdermal delivery of an agent or a combination of agents.
- the microdevice can be a microdevice array comprising a plurality of microstructures formed of a metallic, semi-conductor, glass, ceramic, or polymeric material.
- the microdevice can be microneedle, microknife, or microblade.
- the microdevice comprising microstructures having a nanoscale tip or edge and a microscale body.
- microdevices described herein can be any of microneedles, microblades, microknives, or combinations thereof.
- the term “microneedle” means an elongated element having a ratio of length to largest cross-sectional dimension, of at least about 1:1 or higher.
- the microneedle may have a regular or irregular cross-sectional shape, such as, for example, circular, elliptical, geometric, or a combination thereof.
- the needle may optionally include one or more edges running part of or all of the length of the needle's central axis of elongation.
- the term “microneedle” may also refer to a means that is sufficiently sharp to puncture skin tissue, such as the stratum corneum, to thereby generate nanoconduits.
- microblade and “microknife” both mean an elongated element that is substantially long and thin. For example, having a ratio of length to thickness, of at least about 2:1 or higher.
- Each microblade includes two surfaces that meet at a single long edge. The length of the edge may be oriented parallel to the skin surface, perpendicular to the skin surface, or at an angle to the skin surface.
- a microblade with an edge that is significantly parallel to the skin surface may generate a nanoconduit in the skin that is an elongated opening or channel along the surface of the skin that has a narrow width and a depth into the skin as described above for nanoconduits.
- a microblade with an edge that is significantly perpendicular to the skin surface may generate a nanoconduit in the skin that is an elongated opening in the skin that has a narrow width, or the nanoconduit may have more of a puncture shaped volume wherein the opening has narrow widths in all directions.
- the terms “microblade” and “microneedle” may also refer to a means having an elongated edge that is sufficiently sharp to puncture skin tissue, such as the stratum corneum, to thereby generate nanoconduits.
- a microdevice may comprise one or more microneedles, microblades, or microknives.
- Aspect-ratio is defined as the ratio of the depth or height of a structure to its lateral dimension.
- High-aspect-ratio microstructures typically have an aspect ratio higher than about 5:1 and they may be useful for a variety of purposes.
- the tip of microneedle 6 or the edge of the microblade and microknife 6 needs to be sharp in order to lower the insertion force, while the body of microdevice 7 should be high enough to allow it to completely penetrate stratum corneum.
- a typical size of the needle tip or width of edge on microblades and microknives is smaller than 10 microns, preferably smaller than 5 microns and the height of the microdevices is higher than 20 microns, preferably higher than 50 microns.
- HARMS can thus be used to fabricate microdevices including microneedles, microblades, and microknives for drug delivery through skin or body fluids extraction out of skin.
- Another example of HARMS is nanochannels for microfluidic manipulation and transport.
- HARMS is typically made by Micro-ElectroMechanical Systems (MEMS) and nanofabrication technology that involves a number of thin film deposition, photolithography, etching and electroplating, injection molding, hot embossing, self-assembly, as well as LIGA process.
- MEMS Micro-ElectroMechanical Systems
- a “microneedle array” as used herein refers to a localized arrangement of more than one microneedle, microblade, microknife, or combinations thereof on a surface.
- the localized arrangement may comprise regular or irregular patterns of the microneedles, microblades, or microknives.
- microneedles and/or microblades may be arranged in rows, in random formation, or a combination thereof.
- the microneedle, microblade, microknife, or microneedle array may be present on one or more surfaces of an applicator device.
- the microdevice can further include microchannels and microreservoirs.
- the microdevice or microneedle array may also optionally comprise hollows, voids, non-smooth textures, and/or cavities.
- One possible use of the hollows, voids, non-smooth textures, and/or cavities is as a site to localize, concentrate, or deliver the agent in embodiments where the agent is to be applied to the skin simultaneously with the generation of the nanoconduits.
- the microneedles or microblades comprise hollow channels for delivering an agent via diffusion or active injection, for example from a reservoir.
- the microneedles or microblades do not comprise hollow channels for delivering an agent via diffusion or active injection.
- the microdevices can be made of many different materials or their combinations, including metals, ceramics, polymers and glass.
- the materials are titanium, stainless steel, nickel, alloy of nickel-iron, silicon, silicon oxide, glass, polymethyl methacrylate (PMMA), polyaryletherketone, nylon, PET, poly(lactic acid), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), polycarbonate, and polystyrene. It should have enough mechanical strength to penetrate skin without break and buckle while ensure delivery of drugs, or collect of biological fluids.
- An elastic liposome is an artificial vesicle designed to be like a cell vesicle, and used to deliver drugs or genetic material into a cell. Its bounding membrane is more flexible than that of a liposome, allowing it to deform and pass through openings in a barrier, such as the skin, whose diameters are much smaller than the average vesicle size.
- An elastic liposome is an at least bi-component, most often vesicular, aggregate. The main functional characteristic of the aggregate is the extreme flexibility and permeability of its bilayer-like membrane coating. Its basis is the interdependency of local membrane shape and composition, which makes the bilayer self-regulating and self-optimising. The bilayer is thus capable of stress adaptation, via local and reversible bilayer component demixing. All this makes an elastic liposome into a tool suitable for non-invasive and targeted drug delivery, for example across intact skin.
- a basic elastic liposome is composed of one natural amphiphat (such as phosphatidylcholine) that tends to self-aggregate into vesicles. The latter are then supplemented by at least one bilayer softener (e.g. a biocompatible surfactant).
- the vesicle-like elastic liposome thus normally possesses an aqueous core surrounded by a complex, very fluid and adaptable lipid bilayer.
- an elastic liposome differs from the latter by its more flexible and permeable, “softened” bilayer membrane.
- An elastic liposome vesicle can consequently change shape readily and easily by adjusting relative concentration of its two components in the bilayer to the local stress experienced by the complex bilayer. This can be observed indirectly by studying stress- or deformation-dependent vesicle bilayer elasticity or permeability. In a single experiment, the same goal can be achieved by determining the pressure dependency of elastic liposome suspension-flux through a nano-porous filter (with the pores considerably smaller than the average vesicle size). The rate of resulting transport must grow with driving force (head pressure) non-linearly (often sigmoidally) until maximum flow is reached.
- the delivery formulation described herein includes a carrier that comprises elastic liposomes.
- the liposomes can be nanoparticles containing lipid-encapsulated therapeutic agents.
- the liposomes or nanoparticles are complex, most often vesicular, aggregates.
- the liposomes or nanoparticles can be optimized to attain flexible and self-regulating membrane, which makes the vesicle very deformable.
- These liposomes or nanoparticles can be typically applied on the skin and can be engineered to achieve high drug concentration at or near the site of application, diminish local or systemic adverse side effects, and often increase drug potency.
- the term “high drug concentration” refers to a local concentration enough to achieve desired therapeutic effects without incur significant side-effect.
- Liposome nanoparticles can be formed by known method in the art.
- the method for forming liposome nanoparticles can be thin film dispersion, reverse-phase evaporation, alcohol infusion, extrusion with or without pressure, which are known in the art (see, e.g., Planas M. E.; Gonzalez M. E.; Rodriguez L. et al. Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes. Anesth. Analg 1992. 75(4):615-621; Gregor Cevc, Gabiele Blume, Andreas S, et al.
- the skin pathway for systemic treatment with patches and lipid based agent carries[J] Advanced Drug Delivery Reviews, 18:349 (1996); Gregor Cevc, et al., Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements Biochimica et Biophysica Acta 1564:21-30 (2002); G. Cevc, et al., Overcoming semi-permeable barriers, such as the skin, with ultradeformable mixed lipid vesicles, Transfersomes® liposomes or mixed lipid micelles. Langmuir, 19:10753-10763 (2003); Gregor Cevc, Lipid vesicles and other colloids as drug carriers on the skin Advanced Drug Delivery Reviews 56:675-711 (2004)).
- FIGS. 1A and 1B show two preparations of liposome nanoparticles containing docetaxel.
- the device described herein can be used for transdermal delivery of an agent or a combination of agents to treat, prevent, or ameliorate a body condition in need of treatment.
- the method generally includes treating a skin site of delivery with a microdevice described herein, and delivery an agent to the body of a mammal (e.g., a user or patient).
- Skin is an elastic tissue that deforms when a force is applied.
- An applicator and method is described for applying a microneedle/nanoporation device, including a plurality of microneedles with a gentle impact. The method is used to improve transport of an active agent through skin barrier.
- the present subject matter provides for a method that includes, e.g., pre-treating skin by microneedle array to generate a pre-treated area of skin, and applying to the pre-treated area a wet formulation to allow a therapeutic agent (e.g., drug) or a combination of therapeutic agents to transport through skin.
- a therapeutic agent e.g., drug
- the wet formulation can be in the form of lotion, cream, gel patch, ointment or skin patch.
- an occlusive layer is applied over the wet formulation to aid in transporting the therapeutic agents through skin.
- the agent can be included in the microdevice as a coating with or without a carrier.
- the agent can be delivered with the microdevice being attached to the site of delivery until a desired quantity or duration of delivery is achieved.
- the agent can be separate from the microdevice.
- the skin site chosen for delivery the agent can be pre-treated with the microdevice. The agent can then be applied to the skin site of delivery to allow the agent to penetrate into the body of a user or patient.
- the body condition can be a medical condition or a cosmetic condition.
- Representative medical conditions include, but are not limited to, AIDS, breast cancer, melanoma, liver cancer, lung cancer, blood cancer, pituitary tumors, other cancers, flu, infection, blood disease, cardiac disease, back pain, neck pain, body pain, general pain, arthritis, osteoporosis, headache, depression, smoke, alcoholic, overweight and obesity, menopause, facial hair growth, balding, polycystic ovary syndrome, need of inoculation, need of anesthetics and in particular dermal disease.
- Representative cosmetic conditions include, but are not limited to, skin aging, skin wrinkle, dark spot, skin discoloration, moisturizing, skin lightening, skin whitening, skin firming, skin lifting, acne, wart, infection, irritation, dry skin and oily skin.
- the present microdevices are designed as disposable or re-usable devices.
- the microdevices are disposable.
- the microdevices have coating of active substances on them or not, there are three categories of applications in the delivery of drugs, cosmetic substances and vaccines in the preferred embodiment.
- the microdevices can be used to perforate or scratch stratum corneum. They are then removed immediately and a formulation of an active substance such as a lotion, cream, gel patch, ointment or skin patch with the active substance is applied to the microdevice treated area right away. The formulation will stay on the skin for a pre-defined period, providing sustainable controlled release of an agent such as a drug, or a combination of agents.
- an active substance such as a lotion, cream, gel patch, ointment or skin patch with the active substance is applied to the microdevice treated area right away.
- the formulation will stay on the skin for a pre-defined period, providing sustainable controlled release of an agent such as a drug, or a combination of agents.
- Another embodiment is to store the active agents, as defined below, in the substrate and rely on passive diffusion when the microdevice is in touch with skin.
- the coated microneedles are applied to the skin and stay on the skin for the entire period of treatment.
- the rate of through skin transport can be measured using in vitro or in vivo methods known in the art.
- an area of skin can be pre-treated by the microdevice described herein using an applicator.
- An “applicator device” or “applicator” as used herein refers to a device or object used to generate nanoconduits in the skin.
- the applicator preferably comprises a driving structure, element, mechanism, and/or means for generating nanoconduits in the skin.
- the applicator is preferably used in conjunction with a surface, patch, or reservoir comprising an agent to be delivered.
- the applicator helps to both deliver agent and generate nanoconduits at a single predetermined skin area at a time. Accordingly, in an alternative embodiment, the applicator may simultaneously generate nanoconduits in the skin area and apply a pre-applied agent.
- the applicator may employ vibration of one or more frequencies to create an impact force to generate the nanoconduits.
- the applicator may contain an exchangeable head, connecting to a battery-powered motor with two eccentric wheels, transforming rotation to vibration.
- the vibration can create an impact to the skin through a plurality of microneedles mounted on top of the exchangeable head.
- the frequency of vibration depends on rotation speed and mass distribution of the eccentric wheels and can be in the range of about 10 Hz to about 50000 Hz. In some embodiments, the frequency range can be between about 1000 and about 8000 Hz.
- An ordinary artisan can design and make an applicator accordingly.
- the applicator for mechanical skin treatment comprises:
- a housing having a plurality of walls defining an interior space, the interior space having an upper opening permitting selective access to the interior space of the housing, a cover member being removably couplable to the housing such that the cover is for closing the upper opening of the interior space of the housing;
- microneedle array assembly comprising:
- the base portion of the applicator described above can further comprises a motor assembly being positioned in the base portion, the head portion having a drive assembly being positioned in the head portion, the drive assembly being operationally coupled to a base portion, the base portion outwardly extending from an upper end of the head portion, the motor assembly being operationally coupled to the drive assembly such that the motor assembly is for actuating the drive assembly, the drive assembly being for oscillating the base portion when the drive assembly is actuated by the motor assembly.
- the applicator described above can further comprise a head portion having a plurality of microneedles extending from the base portion, the microneedles being adapted for treat the skin when the microneedle head portion is oscillated by the drive assembly.
- the applicator described above can further comprise a motor assembly having a motor, the motor having a shaft extending from the motor, the motor being for actuating the shaft, the shaft being for operationally coupling to the drive assembly of the base and head portions such that actuation of the shaft actuates the drive assembly, a power source being operationally coupled to the motor such that the power supply is for providing power to the motor.
- the applicator described above can include a heavy eccentric mass designed to produce vibration upon actuation of the motor, wherein the motor is actuated to bring the base and head portions into vibration so that skin treatment is practiced through the aid of the vibration, the microneedle application method comprising the steps of:
- the applicator described above can further include a motor assembly having a switch, the switch being operationally coupled between the power supply and the motor, the switch being for controlling power from the power supply to the motor.
- kits for delivering an agent to a mammal comprising:
- the driving force can be, but is not limited to, ultrasound, iontophoresis, radio frequency, laser light, heat gradient, or a combination thereof.
- kits may further comprises an applicator of the microdevice for applying the microdevice to an area of skin of a mammal; and/or a driving force mechanism for driving the bioactive agent to transport through the stratum corneum of the area of skin into the mammal.
- the driving force mechanism can comprise ultrasound, radio frequency, heat gradient, laser light, iontophoresis device, or a combination thereof.
- the applicator is a mechanical applicator.
- kits are particularly useful in treating a mammal having a medical condition.
- Some potential medical conditions treatable by the present kits include, but are not limited to, chronic back pain, a cancer, pre-surgery pain management, operation room pain management, cancer pain, post-surgery pain and lower back pain, and post-surgery pain management.
- the agent used in the kits can be, but is not limited to, a natural or synthetic vaccine selected from the group consisting of proteins, peptides, paclitaxel, docetaxel, vaccines, protein vaccines, peptide vaccines, gene vaccines, DNA vaccines, and combinations thereof.
- the vaccine can be against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, Haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS, and/or cholera.
- the agent is a pain relieving agent.
- the pain relieving agent can be lidocaine, tetracaine, dyclonine, or a combination of thereof.
- the formulation used in the present kits can comprise elastic liposomes encapsulating the agent.
- the elastic liposomes can optionally comprise deformable nanoparticles.
- the formulation in the present kits does not comprises elastic liposomes.
- the formulation can be a topical or systemic delivery formulation selected from a skin patch, cream, ointment, or lotion. In a preferred embodiment, the formulation is a wet skin patch.
- active agents or active substances that can be delivered using microdevices are therapeutic agents.
- therapeutic agent is used here to refer to active agent that can treat, prevent, and ameliorate a body condition or skin condition that needs treatment.
- a list of examples includes: drugs, vaccines, peptides, proteins, genes, DNAs, nutraceuticals and cosmetics.
- the drugs can be administered topically or systemically.
- drugs as active agents include, but not limited to antibiotics, hormones, steroids, anti-inflammatory drugs, protein drugs, DNA drugs whether natural or synthesized, such as Recombinant Erythropoietin (rhEPO), Taxol®, Interferon-alpha-1b, Interferon beta, Interferon gamma, Emla®, Fluorouracil, Lidocaine, Salicylic acid, Pureriran, eflornithine hydrochloride, spironolactone, flutamide, insulin, nanoparticle drugs, Epidural, recombinant human parathyroid hormone, growth hormone, thyroid, cortisol, estrogen, progesterone, and testosterone.
- rhEPO Recombinant Erythropoietin
- Taxol® Interferon-alpha-1b
- Interferon beta Interferon beta
- Interferon gamma Emla®
- Fluorouracil Lidocaine
- Salicylic acid Pureriran, ef
- vaccines active agents include, but not limited to: vaccine against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, Haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS and cholera.
- cosmetic substances as active agents include, but not limited to: botllinum toxin type A, hyaluronic acid and its derivatives, acetyl hexapeptide-3, vitamin A, vitamin C, vitamin E, alpha-hydroxyacids, collagen and hormones. Diagnostic reagents are also included. Examples include, but not limited to, quantum dots, functionalized nanoparticles, magnetic particles for diagnostic purpose.
- the dosage of the agent can vary according to the medical conditions.
- the effective amount of an agent that has been well established in the art can be publicly available. Such information can be obtained from the U.S. Food and Drug Administration (FDA), e.g., FDA website.
- FDA U.S. Food and Drug Administration
- LidoDerm® publishes this type of information.
- the agent is a pain relieving drug for neuropathic or nociceptive pain management.
- pain relieving drug includes, but is not limited to, Lidocaine; Prilocaine, Tetracaine, Ibuprofen; Acetaminophen; Capsaicin; EMLA®; Tramadol (Ultram); Gabapentin, Tramadol hydrochloride, Corticosteroids, Sufentanil, Clonidine, Bupivacaine, Tricyclic antidepressants, opioid analgesics such as morphine, Hydromorphone, naloxone (Narcan), Talwin, Nubain, Stadol, Fentanyl, Meperidine, Hydrocodone, Codeine, Oxycodone; non-selective NSAIDs such as Celecoxib (Celebrex), rofecoxib (Vioxx), valdecoxib (Bextra); or combinations thereof.
- the pain relieving drug described here includes, but is not limited
- the active agent can be muscle relaxants, which include, but are but not limited to, Benzodiazepines; Methocarbamol; Carisoprodol; Chlorzoxazone; Metaxalone; Cyclobenzaprine, or combinations thereof.
- the muscle relaxants described herein can specifically exclude any of the drug/agents listed herein.
- the present subject matter provides a device 10 for delivery of therapeutic active agent as defined above across the skin barrier, stratum corneum layer. Once the substances pass the stratum corneum, there is less resistance for the substances to diffuse into the subsequent layers of the skin: epidermis and dermis. The substances will be absorbed by micro blood vessels and lymphatics in the dermis layer and delivered to entire human body.
- Microdevices disclosed in the current subject matter can enhance through skin penetration of molecules of molecular weight lower than 500 Dalton. In some embodiments, microdevices can also enable through skin transport of large molecules of molecular weight higher than 500 Dalton.
- the molecular weight of Bovine Serum Albumin is 66,000 Dalton.
- the molecular weight of Botulinum Toxin Type A is 150,000 Dalton and the molecular weight of Interferon-Alpha-1b is 17,000 Dalton.
- the present systems permit the agent to permeate the skin at least 10 times faster than in a system where the formulation is applied to an area of skin which does not contain any generated nanoconduits.
- the agent can permeate the skin to cumulative amounts at least 10 times higher than in a system where the formulation is applied to an area of skin which does not contain any generated nanoconduits.
- the drug delivery of the present subject matter can be achieved by preparing an area of skin to generate a prepared area of skin and then applying an agent or drug to the prepared area of skin to allow a pre-defined amount of the drug or agent to pass through the stratum corneum of the prepared area of skin.
- the prepared area of skin can be prepared using a device, e.g., a spring-powered mechanical applicator to apply microneedles to an area of skin.
- the mechanical applicator can be any structure or design and can cause a mechanical force to be applied to the microneedle against the area of skin to generate pores or channels in the stratum corneum in the area of skin in a pre-defined size and depth. The size and depth of the pores or channels can facilitate the release of controlled amount of an agent or drug through skin.
- the prepared area of skin can be further treated using an ultrasound device or a mechanical vibrator to apply microneedles to an area of skin.
- the ultrasound device or mechanical vibrator can cause a pre-set mechanical force to be applied to the microneedle against the area of skin to generate pores or channels in the stratum corneum in the area of skin in a pre-determined size and depth.
- the size and depth of the pores or channels can provide for controlling the amount of an agent or drug of delivery. It is noteworthy that the ultrasound device or mechanical vibrator can be an effective way to perforate an elastic skin tissue to generate pores or channels in a pre-defined size and/or depth.
- the prepared area of skin can be prepared in a pre-defined size or dimension (e.g., a dimension of 1 cm.times.1 cm) using an array of microknives or microblades by slicing or lacerating the stratum corneum in an area of skin to generate nanochannels in a pre-defined depth and/or dimension.
- the dimension and/or depth of the laceration and the dimension of the prepared area of skin can provide for controlling the amount of an agent or drug.
- Allowing an agent or drug to pass through the stratum corneum of a prepared area of skin can be achieved by a variety of mechanisms.
- the allowing can be achieved by diffusion of the agent or drug from a topical composition (e.g., a formulation such as lotion, cream, gel patch, ointment or skin patch) into the body of a patient or user via the prepared area of skin.
- a driving mechanism for example, iontophoresis, sonophoresis, radiofrequency (RF) or heat or a combination of these to actively drive agents through the skin.
- Iontophoresis, sonophoresis, radiofrequency (RF) or heat are well developed mechanisms for promoting or enhancing drug delivery.
- Some examples of iontophoresis systems in drug delivery are described in websites online.
- Some examples of sonophoresis systems in drug delivery are described in Becker B, Helfrich S, Baker E, et al. Ultrasound with topical anesthetic rapidly decreases pain of intravenous cannulation. Academic Emergency Medicine 2005; 12:289-295; Katz N, Shapiro D, Herrmann T, et al., Rapid onset of cutaneous anesthesia with EMLA cream after pretreatment with a new ultrasound-emitting device. Pain Trials Center, Brigham and Women's Hospital, Boston, Mass.; Mitragotri S, Kost J, Low frequency sonophoresis: A Review. Advanced Drug Delivery Reviews 2004; 56:589-601.
- Botulinum Toxin Type A is a toxin that blocks neuromuscular transmission when it is injected in small amounts (e.g., 10 units per 0.1 ml injection volume) into specific muscles to treat and reduce wrinkles on the face.
- the maximum dosage recommended as a single injection for any one muscle at any spot is 25 units. If overdosed or the injection is incorrectly performed, the patient can be left with an immobile face or droopy eyelids till the effect of the injection wears off.
- the side effects include numbness, swelling and headaches.
- Transdermal delivery of an agent through skin treated by the microdevice described herein has less dependency on molecular weight of the agent.
- any cosmetic substances can be delivered using microdevices herein. Local concentration can be adjusted through loading and composition for controlled release, as well as a combination of microneedle height, density, size and shape.
- Hyaluronic acid is a substance that exists naturally in the body. A major important function of hyaluronic acid is to carry and bind water molecules. Stabilized non-animal hyaluronic acid does not contain animal protein and does not require a skin test prior to treatment. It is thus a preferred embodiment of this subject matter to use microdevices to delivery locally stabilized non-animal hyaluronic acid to treat wrinkles and facial lines.
- acetyl hexapeptide-3 is to provide for local delivery of acetyl hexapeptide-3.
- This molecule is a non-toxic, non-irritant compound that modulates the excessive stimulation of the facial muscles, relaxing facial tension and it can reduce and prevent the formation of new wrinkles due to over-stimulation of facial muscles. More examples include but not limited to: vitamin A, vitamin C, vitamin E, alpha-hydroxyacids, hormones, or combinations thereof.
- the microdevice provided herein can be used for topical or systemic delivery of vaccines below the stratum corneum layer.
- the type of vaccines includes conventional vaccines as well as protein, peptide, DNA vaccines and the like as previously described.
- Vaccination can be performed by treating a skin site with the microdevice and then delivering a vaccine composition to a user.
- the microdevice provided herein can be used for topical or systemic delivery of drug with large molecules.
- the drug can be a protein or peptide.
- the drug can be a chemical drug with a relatively high molecular weight.
- the term large molecule refers to a drug having a molecular weight higher than about 300 Daltons.
- the molecule can have molecular weight higher than about 500 Daltons, higher than about 1000 Daltons, higher than about 5,000 Daltons, higher than about 10,000 Daltons, higher than about 20,000 Daltons, higher than about 50,000 Daltons, higher than about 100,000 Daltons, higher than about 200,000 Daltons, higher than about 500,000 Daltons, or higher than about 1,000,000 Daltons.
- the drug can be paclitaxel, docetaxel, insulin, Recombinant Erythropoietin (rhEPO), Interferon-alpha, Interferon beta, Interferon gamma, nanoparticle drugs, recombinant human parathyroid hormone, growth hormone, thyroid, cortisol, estrogen, progesterone, and testosterone.
- rhEPO Erythropoietin
- Interferon-alpha Interferon beta
- Interferon gamma nanoparticle drugs
- recombinant human parathyroid hormone growth hormone, thyroid, cortisol, estrogen, progesterone, and testosterone.
- vaccines active agents include, but not limited to: vaccine against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, Haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS and cholera.
- cosmetic substances as active agents include, but not limited to: botulinum toxin type A, hyaluronic acid and its derivatives, acetyl hexapeptide-3, vitamin A, vitamin C, vitamin E, alpha-hydroxyacids, collagen and hormones. Diagnostic reagents are also included. Examples include, but not limited to, quantum dots, functionalized nanoparticles, magnetic particles for diagnostic purpose.
- the microdevice described herein can be used for pain management.
- the microdevice can be used to facilitate transdermal delivery of a pain relieving agent or a combination of them so as to treat, reduce or prevent pain.
- a skin site can be treated with the microdevice and then a pain relieving agent or drug composition can be applied to the treated site, allowing transdermal delivery of these agents to a user.
- the pain relieving agent can be any pain relieving agent approved by FDA or used in medical practice elsewhere in the world.
- the pain relieving drug can be, but are not limited to, NSAIDs, COX-2 inhibitors, steroids, muscle relaxants.
- NSAIDs such as Lidocaine; Prilocaine, Tetracaine, Ibuprofen; Acetaminophen; Capsaicin; EMLA®; Tramadol (Ultram); Gabapentin, Tramadol hydrochloride, Corticosteroids, Sufentanil, Clonidine, Bupivacaine, Tricyclic antidepressants, opioid analgesics such as morphine, Hydromorphone, naloxone (Narcan), Talwin, Nubain, Stadol, Fentanyl, Meperidine, Hydrocodone, Codeine, Oxycodone; non-selective NSAIDs such as Celecoxib (Celebrex), rofecoxib (Vioxx
- the pain management can be carried out according to a management regime prescribed by a treating doctor.
- the pain management is chronic or acute pain management.
- the pain management regime can be but not limited to, lower back pain, post-herpetic neuralgia, cancer pain, diabetic neuropathy, phantom limb pain, spinal stenosis/sciatica, spinal mets, HIV pain, post-surgery pain, pre-surgery preparation, operation room pain management, pain caused invasive medical procedures such as needle injection, cannulation.
- the current subject matter involves topical or systemic delivery of pain relieve agent to deep tissues through assistance of a combination of active transdermal delivery methods such as sonophoresis, iontophoresis, laser ablation, radio frequency or heat treatment after the startum corneum are treated with the said microdevices.
- active transdermal delivery methods such as sonophoresis, iontophoresis, laser ablation, radio frequency or heat treatment after the startum corneum are treated with the said microdevices.
- the present systems and methods are useful for treating cancer.
- the microdevices herein preferably deliver drug molecules through skin at a rate that is sufficient to maintain a therapeutic useful concentration in plasma.
- the size, density, shape and length of the microdevices can be adjusted to meet the delivery requirement.
- the microdevices can be further coated with a composition that contains active therapeutic molecules, or vaccines, or cosmetic substances, together with polymer binders such as chitosan, carbopol 934P, cellulose and starch to form a dry film. Additional additives of binders, rheology modifiers, surface active agents, stabilizer, rehydration agents may be used.
- the special composition can control the dissolve rate of the active drug molecule and regulate the drug release rate.
- the microdevices may be integrated with embedded microfluidic channels that connect to microreservoirs.
- the present the methods result in a plateau plasma concentration of agent, wherein the plateau is preferably maintained within 80% of the peak concentration from 10 hours after first contact and up to at least 24 hours after first contact.
- the plateau can be maintained within 80% of the peak concentration from 10 hours after first contact and up to at least 48 hours after first contact.
- the agents herein have a “drug permeation”, meaning as the amount of agent (mg, or mmol) diffused across the skin barrier within a defined time.
- the method of delivering an agent, or a combination of agents may include applying an occlusive layer.
- the occlusive layer may be applied over the applied agent and directly on the prepared area of skin, or the area of skin, such that the occlusive layer prevents air from coming into contact with the prepared area of skin following the removal of the applicator and microdevice from the skin.
- the occlusive layer is advantageous for preventing evaporation of the agent or combination of agents, and most importantly, allows for increased penetration of an active agent across the skin.
- the occlusive layer is useful for preventing evaporation of the wet formulation and provides increased penetration of the active agent across the skin.
- an occlusive layer is applied directly on the prepared area of the skin such that the occlusive layer prevents air from coming into contact with the prepared area of skin following the removal of the applicator and microdevice.
- the prepared area of skin is generated by applying the applicator to an area of the skin, and subsequently, the occlusive layer is applied directly on the abraded area of skin, either with or without a wet formulation.
- the occlusive layer may be placed directly on the prepared area of skin to prevent air or other fluids from entering the abraded skin area, other than the et formulation comprising the agent.
- the occlusive layer in order to prevent air from contacting the prepared area of skin, the occlusive layer must contact the entire abraded area.
- FIG. 2 shows the difference for drug delivery between occlusive and non-occlusive treatment following microneedle pre-treatment. From the data shown in FIG. 2 , it is clearly evident that applying an occlusive layer after microneedle pre-treatment significantly improves drug delivery since the rate of penetration increases. When compared to non-occlusive treatment after microneedle pre-treatment, or even non-occlusive pretreatment with no microneedle pre-treatment, the rate of penetration is substantially less. In fact, the drug delivery data shown in FIG. 3 shows that the present method unexpectedly provides 72 hours of extended drug release.
- the data from the graph shown in FIG. 2 is provided in the Table 1, which shows the effect of the occlusive layer on penetration.
- Table 1 shows comparative data of the percent penetration of an active agent (docetaxel) in elastic liposomes across skin under four different sets of conditions, where the active is applied to the skin with or without microneedle preparation of skin or use of an occlusive layer:
- the data in Table 1 shows that adding an occlusive layer does not change the percent penetration over 24 hours of the agent across skin not prepared with microneedles.
- the two data sets (“occlusively without microneedles” vs. “non-occlusively without microneedles”) show statistically the same amount of penetration. In other words, the evidence shows that adding an occlusive layer does not increase the penetration of the agent across unprepared skin.
- FIG. 2 shows that adding an occlusive layer to skin prepared with microneedles unexpectedly and significantly increases the percent penetration of the active across the prepared skin. This unexpected increase in penetration is due to the combination of the presence of microneedle prepared skin and adding an occlusive layer to the microneedle prepared skin.
- FIG. 6 shows a graph of Trans-Epidermal Water Loss with or without microneedle application.
- the X-axis represents the time in seconds and the Y-axis represents the Trans-Epidermal Water Loss (TEWL).
- the diamond shaped data points represent the TEWL baseline, and the square shaped data points represent the increase of TEWL after the treatment with the present microdevice.
- the curve of the square shaped data points decreases over time and eventually merges with the diamond shaped data points at about 200 seconds. This indicates that the skin barrier was initially compromised and penetrated by the microdevice and the skin quickly recovers in about 120-200 seconds or 20-30 minutes.
- FIG. 7 shows a graph of serum insulation concentration with an occlusive layer applied.
- the graph shows the prolife of Novolin R® serum insulin concentration vs. time in a diabetic rat after the administration of insulin by the present microdevice.
- the serum concentration reached 110 ⁇ 5.37 ⁇ IU/ml and stayed relatively constant at this level when the occlusive layer was applied. This indicates that the delivery channels were kept open to meet the basal insulin delivery need.
- the serum concentration rapidly dropped after the removal of the occlusive layer, indicating that the pores closed and the insulin delivery source was cut off.
- tape stripping removes the SC mechanically, while acetone treatment extracts lipids from the SC.
- Restoration of barrier function occurs in a similar amount of time following tape stripping and acetone treatment.
- the pores of the skin generally stay open for a very short period of time providing a limited window for drug delivery.
- the present microdevice and method overcomes these deficiencies.
- the present subject matter significantly improves drug delivery since the rate of penetration increases and allows extended drug delivery, i.e., 72 hours as shown in FIG. 3 .
- microneedle can collect an extremely low sample volume of body fluids from a patient and allow rapid point-of-care analysis of body fluids.
- the sample volume extracted is below 0.1 microliter, typically around 0.01 microliter.
- the HARMS were fabricated using MEMS (Micro-Electro-Mechanical Systems) microfabrication technology.
- the typical fabrication process involved lithography, wet etch and dry etch, thin film deposition and growth, electroplating, as well as injection molding and hot embossing.
- One example of fabrication method was to use Bosch process that allowed deep Si etch. It formed HARMS suitable either as device body or mold for further processing.
- the aspect ratio was higher than 5:1, independent to feature size and pattern shape as long as the features can be defined by lithography.
- Another fabrication method was KOH or TMAH wet etch of single crystal Si substrate that is ⁇ 100> orientation or ⁇ 110> orientation.
- Yet another fabrication method was using HF solution to electrochemically form porous Si structures.
- Metals was used for the fabrication of HARMS through a maskless process called electropolishing starting from a structure fabricated by traditional machining methods such as cutting, electro-discharge machining, milling, grinding, polishing and drilling. Use of any single method herein or a combination of these methods as further disclosed in the examples below led to the form of desired HARMS disclosed in the current subject matter.
- FIGS. 2 and 3 showed the efficacy of transdermal delivery of agents of the present subject matter.
- an area of skin was pre-treated with the microneedles described above.
- a formulation of a fluorescence labeled albumin (molecular weight is 66,000) was applied and successfully transport them through skin ( FIG. 3 ).
- the pore formed by the microneedles will not completely be closed within 72 hours after application of the microneedles.
- FIG. 2 shows Penetration (%) of docetaxel in elastic liposomes with or without microneedle.
- FIG. 4 shows delivery of interferon via different methods. The effectiveness of various delivery methods was assessed by measurement of interferon activity: (a) microneedle with a wet interferon gel on the microneedles, (b) microneedle with a wet interferon gel patch on skin pre-treated with microneedles, (c) subcutaneous injection, and (d) wet interferon gel without microneedle as control sample.
- FIG. 5 shows delivery of interferon with a dry formulation. As FIG. 5 shows, when the patch is dried, the delivery rate dropped dramatically.
- FIGS. 4 and 5 show that delivery of interferon using a dry patch is less effective as it is using a wet patch.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Medicinal Preparation (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is a continuation in part application of U.S. patent application Ser. No. 11/961,816, filed on Dec. 20, 2007, which claims benefit of U.S. Provisional Patent Application No. 60/876,948 which was filed on Dec. 22, 2006. The contents of application Ser. No. 11/961,816 and
provisional application 60/876,948 are incorporated by reference herein in their entirety. - The present application relates to a microdevice for transdermal delivery of an active substance and methods of using the same.
- Major reasons for the success of transdermal delivery were the avoidance of first-pass metabolism and ease of use. This increases drug bioavailability in comparison to other delivery methods. Transdermal Drug Delivery Systems (DDS) can also deliver drugs at a steady rate to achieve a sustainable release, which is an additional advantage. However, transdermal drug delivery methods have their drawbacks. Most important is the fact that conventional transdermal system (TTS) technology is only suited for delivering relatively small drugs across the skin. It also suffers from slow onset, because of the outer skin barrier layer, stratum corneum, that limits the through skin drug transport.
- New transdermal drug delivery methods are therefore required to drive future growth in transdermal product markets. Biological products would also profit greatly from new, non-invasive delivery technology to replace hypodermic needle injection that is the current standard. The original players in the transdermal field failed to introduce such improvements, which were then introduced by a number of innovator companies.
- Broadly speaking, two different new approaches for transdermal drug delivery are currently being pursued: (1) nanoporation/minimum abrasion using a physical device, and (2) nanocarriers using lipid-encapsulated formulation. Sonoporation, thermoporation) use of very fine and short needles belong to the former; ultradeformable carriers (such as Transfersome®, Ethosomes® or fluid liposomes) are examples for the latter. Any of these can deliver small or large molecules across the skin. Some examples of transdermal delivery are described in U.S. Pat. Nos. 7,094,423; 7,049,140; 7,041,870; 7,037,499; 7,034,126; 7,033,598; 7,014,855; 6,991,805; 6,982,084; and 6,979,729.
- However, there is a continuing need for an improved, disposable transdermal delivery device for effective delivery of substances in a controlled manner.
- It is an objective of this subject matter to combine both nanocarriers and nanoporation methods to create new transdermal drug delivery vehicles.
- It is a further objective of this subject matter to disclose a mechanical applicator to facilitate the application of nanoporation devices.
- It is a further objective of this subject matter to disclose a wet device/drug combination method to deliver drug transdermally. The device/drug combination includes, but is not limited to any one or more of the following: (1) pre-treating the mammal using the device, then applying the drug to the mammal; (2) applying the drug to the mammal, then treating the mammal with the device; (3) temporarily anchoring the drug onto the device, then treating the mammal with the device/drug system.
- It is a further objective of this subject matter to provide an occlusive layer useful for increasing penetration of an active agent applied to the skin after nanoporation and/or application of the wet formulation.
- In some embodiments, the method of delivering an agent described herein includes: (1) applying an applicator to a microdevice to cause the microdevice to contact an area of skin of a mammal (e.g., patient) to generate a prepared area of skin comprising a plurality of nanopores or nanochannels through the stratum corneum in a defined area of skin, (2) applying a wet formulation comprising the agent to the area of skin being prepared either before or after the microdevice has generated the plurality of nanopores or nanochannels in the prepared area of skin, (3) applying an occlusive layer over the agent and directly on the prepared area of skin such that the occlusive layer prevents air from coming into contact with the prepared area of skin following the removal of the applicator and microdevice from the skin, and (4) causing an effective amount of an agent to deliver to the patient through the nanopores or nanochannels in the stratum corneum. The microstructure can be coated with a composition comprising the agent. In some embodiments, the causing is by applying a wet formulation including liposome nanoparticles encapsulating the agent and causing the agent to transport through the stratum corneum into the mammal.
- In some embodiments, the present subject matter provides an applicator of the microdevice described herein.
-
FIGS. 1A and 1B show two preparations of liposome nanoparticles containing docetaxel. -
FIG. 2 shows penetration (%) of docetaxel in elastic liposomes with or without microneedle and with or without an occlusive layer. -
FIG. 3 shows fluorescence labeled docetaxel encapsulated within elastic liposome nanoparticles being successfully transported through skin. -
FIG. 4 shows delivery of interferon via different methods. -
FIG. 5 shows delivery of interferon with a dry formulation. -
FIG. 6 shows a graph of Trans-Epidermal Water Loss with or without microneedle application. -
FIG. 7 shows a graph of serum insulation concentration with an occlusive layer applied. - The present subject matter provides high-aspect-ratio microstructures (HARMS) and methods of using the same. The present subject matter also provides methods of using the device for transdermal delivery of drugs, vaccines, diagnostic agents and cosmetic substances and sampling of body fluids for treating, preventing, or ameliorating a medical condition of a mammal such as a human being. In some embodiments, the method comprises treating a topical site of a mammal using a device, and applying an effective amount of an agent to the topical site to allow the agent to penetrate into the body of the mammal. The device can include an array of microstructures. The microstructure can have an aspect ratio of about 5:1, 10:1, 15:1, 20:1 or higher.
- In some embodiments, the present subject matter provides a system for topical or systemic delivery of an agent for a medical condition in a mammal (e.g., a patient). The system comprises: (1) a microdevice comprising an array of microstructures, (2) an applicator for applying the microdevice to an area of skin of a patient to generate a prepared area of skin comprising a plurality of nanopores or nanochannels in stratum corneum of the prepared area of skin, and (3) a delivery mechanism for causing the agent to be delivered to the mammal through the nanopores or nanochannels in the stratum corneum of the prepared area of skin. In some embodiments, the microdevice can comprise nanoscale tips and microscale body that can have an aspect ratio of about 5:1, 10:1, 15:1, 20:1 or higher.
- In some embodiments, the present subject matter provides a method of delivering an agent for a medical condition to a mammal. The method comprises: (1) applying an applicator to a microdevice to cause the microdevice to contact an area of skin to generate a prepared area of skin comprising a plurality of nanopores or nanochannels through the stratum corneum of the area of skin, (2) applying a composition comprising the agent to the prepared area of skin, (3) applying an occlusive layer over the area of skin, and (4) causing an effective amount of the agent to deliver to the patient through the nanopores or nanochannels in the stratum corneum.
- In some embodiments, the method of delivering an agent described herein includes: (1) applying a composition comprising the agent to an area of skin, (2) applying an applicator to a microdevice to cause the microdevice to contact the area of skin to generate a plurality of nanopores or nanochannels through the stratum corneum of the area of skin, (3) applying an occlusive layer over the area of skin, and (4) causing an effective amount of the agent to deliver to the patient through the nanopores or nanochannels in the stratum corneum.
- In some embodiments, the method of delivering an agent described herein includes: (1) applying an applicator to a microdevice to cause the microdevice to contact an area of skin of a mammal (e.g., patient) to generate a prepared area of skin comprising a plurality of nanopores or nanochannels through the stratum corneum of the area of skin, (2) applying an occlusive layer over the area of skin, and (3) causing an effective amount of an agent to deliver to the patient through the nanopores or nanochannels in the stratum corneum. The microdevice can be coated with a composition comprising the agent. In some embodiments, the causing is by applying a wet formulation including elastic liposomes comprising liposome nanoparticles encapsulating the agent and causing the agent to transport through the stratum corneum into the mammal. In some embodiments, the wet formulation does not include elastic liposomes.
- As used herein, the term “composition” sometimes can be used interchangeably with the term “formulation.” The term “wet formulation” refers to any form of wet formulation. In some embodiments, a wet formulation can be a skin patch, cream, ointment, or lotion. In some embodiments, the wet formulation can include elastic liposomes comprising liposome nanoparticles encapsulating an agent. In some embodiments, the wet formulation can include an agent, but not elastic liposomes.
- As used herein, the term “agent” refers to any diagnostic, therapeutic, or preventive agents. The term “agent” is sometimes interchangeably referred to as “active agent,” “bioactive agent,” or “active substance.”
- Skin has a biological barrier called stratum corneum in its outer layer. This layer of about 10-25 microns thick prevents most of the molecules from penetrating through the skin. The layer below the stratum corneum is called viable epidermis. Epidermis is between 50 to 100 micron thick. The viable epidermis layer has no blood vessels and the molecules in this layer can be transported to and from the dermis, a layer under the viable epidermis, which is between 1 to 3 mm thick. There are blood vessels, lymphatics and nerves in dermis layer. To date, for example, a skin patch is only able to deliver drug molecules of less than 500 Da. In addition, these small molecules are typically limited to hydrophobic ones.
- Successful transdermal delivery of therapeutic drugs, vaccines and cosmetic substances needs a way to transport molecules, especially large molecules, through the skin barrier, i.e., the stratum corneum. The substance can be delivered into the skin in any form acceptable for pharmaceutical requirements, but a gel composition is preferred to achieve controlled release of the active ingredient(s).
- The microdevice described herein can be used for effective transdermal delivery of an agent or a combination of agents. The microdevice can be a microdevice array comprising a plurality of microstructures formed of a metallic, semi-conductor, glass, ceramic, or polymeric material. In some embodiments, the microdevice can be microneedle, microknife, or microblade. In some embodiments, the microdevice comprising microstructures having a nanoscale tip or edge and a microscale body.
- The microdevices described herein can be any of microneedles, microblades, microknives, or combinations thereof. As used herein, the term “microneedle” means an elongated element having a ratio of length to largest cross-sectional dimension, of at least about 1:1 or higher. The microneedle may have a regular or irregular cross-sectional shape, such as, for example, circular, elliptical, geometric, or a combination thereof. The needle may optionally include one or more edges running part of or all of the length of the needle's central axis of elongation. The term “microneedle” may also refer to a means that is sufficiently sharp to puncture skin tissue, such as the stratum corneum, to thereby generate nanoconduits.
- As used herein, the terms “microblade” and “microknife” both mean an elongated element that is substantially long and thin. For example, having a ratio of length to thickness, of at least about 2:1 or higher. Each microblade includes two surfaces that meet at a single long edge. The length of the edge may be oriented parallel to the skin surface, perpendicular to the skin surface, or at an angle to the skin surface. A microblade with an edge that is significantly parallel to the skin surface may generate a nanoconduit in the skin that is an elongated opening or channel along the surface of the skin that has a narrow width and a depth into the skin as described above for nanoconduits. A microblade with an edge that is significantly perpendicular to the skin surface may generate a nanoconduit in the skin that is an elongated opening in the skin that has a narrow width, or the nanoconduit may have more of a puncture shaped volume wherein the opening has narrow widths in all directions. The terms “microblade” and “microneedle” may also refer to a means having an elongated edge that is sufficiently sharp to puncture skin tissue, such as the stratum corneum, to thereby generate nanoconduits. A microdevice may comprise one or more microneedles, microblades, or microknives.
- Aspect-ratio is defined as the ratio of the depth or height of a structure to its lateral dimension. High-aspect-ratio microstructures (HARMS) typically have an aspect ratio higher than about 5:1 and they may be useful for a variety of purposes. In the current subject matter, the tip of
microneedle 6 or the edge of the microblade andmicroknife 6 needs to be sharp in order to lower the insertion force, while the body of microdevice 7 should be high enough to allow it to completely penetrate stratum corneum. A typical size of the needle tip or width of edge on microblades and microknives is smaller than 10 microns, preferably smaller than 5 microns and the height of the microdevices is higher than 20 microns, preferably higher than 50 microns. The aspect ratio of these microdevices, in a preferred embodiment of the current subject matter, are higher than 10:1 with the size of the tip and edge smaller than 5 microns and the height of microdevices higher than 50 microns. HARMS can thus be used to fabricate microdevices including microneedles, microblades, and microknives for drug delivery through skin or body fluids extraction out of skin. Another example of HARMS is nanochannels for microfluidic manipulation and transport. HARMS is typically made by Micro-ElectroMechanical Systems (MEMS) and nanofabrication technology that involves a number of thin film deposition, photolithography, etching and electroplating, injection molding, hot embossing, self-assembly, as well as LIGA process. - A “microneedle array” as used herein refers to a localized arrangement of more than one microneedle, microblade, microknife, or combinations thereof on a surface. The localized arrangement may comprise regular or irregular patterns of the microneedles, microblades, or microknives. For example, microneedles and/or microblades may be arranged in rows, in random formation, or a combination thereof. The microneedle, microblade, microknife, or microneedle array may be present on one or more surfaces of an applicator device.
- The microdevice can further include microchannels and microreservoirs. The microdevice or microneedle array may also optionally comprise hollows, voids, non-smooth textures, and/or cavities. One possible use of the hollows, voids, non-smooth textures, and/or cavities is as a site to localize, concentrate, or deliver the agent in embodiments where the agent is to be applied to the skin simultaneously with the generation of the nanoconduits. In some embodiments, the microneedles or microblades comprise hollow channels for delivering an agent via diffusion or active injection, for example from a reservoir. In other embodiments, the microneedles or microblades do not comprise hollow channels for delivering an agent via diffusion or active injection. Some examples of the microdevice are described in U.S. application Ser. Nos. 10/908,584, filed on May 18, 2005 and Ser. No. 11/510,078, filed on Aug. 25, 2006. The teachings of both applications are incorporated herein in their entirety by reference.
- The microdevices can be made of many different materials or their combinations, including metals, ceramics, polymers and glass. Examples of the materials are titanium, stainless steel, nickel, alloy of nickel-iron, silicon, silicon oxide, glass, polymethyl methacrylate (PMMA), polyaryletherketone, nylon, PET, poly(lactic acid), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), polycarbonate, and polystyrene. It should have enough mechanical strength to penetrate skin without break and buckle while ensure delivery of drugs, or collect of biological fluids. They can be sterilizable using established protocols (see, for example, moist heat, ethylene oxide or radiation sterilization as stated by ANSI/AAMI/ISO 11134:1993, ANSI/AAMI/ISO 11135:1994 and ANSI/AAMI/ISO 11137:1994, the contents of which are incorporated herein by reference in their entirety).
- An elastic liposome is an artificial vesicle designed to be like a cell vesicle, and used to deliver drugs or genetic material into a cell. Its bounding membrane is more flexible than that of a liposome, allowing it to deform and pass through openings in a barrier, such as the skin, whose diameters are much smaller than the average vesicle size. An elastic liposome is an at least bi-component, most often vesicular, aggregate. The main functional characteristic of the aggregate is the extreme flexibility and permeability of its bilayer-like membrane coating. Its basis is the interdependency of local membrane shape and composition, which makes the bilayer self-regulating and self-optimising. The bilayer is thus capable of stress adaptation, via local and reversible bilayer component demixing. All this makes an elastic liposome into a tool suitable for non-invasive and targeted drug delivery, for example across intact skin.
- Another beneficial consequence of high bilayer flexibility is the increased elastic liposome affinity to bind and retain water. Ultradeformable elastic liposome vesicles put in a dry environment therefore seek to find water richer region. This forces elastic liposome vesicles applied on open skin to penetrate the skin barrier in a search for adequate hydration. The resulting vesicle migration is a consequence of continuous bilayer adaptation and deformation, but must not compromise unacceptably either the vesicle integrity or the protective skin barrier properties in real-life applications.
- A basic elastic liposome is composed of one natural amphiphat (such as phosphatidylcholine) that tends to self-aggregate into vesicles. The latter are then supplemented by at least one bilayer softener (e.g. a biocompatible surfactant). The vesicle-like elastic liposome thus normally possesses an aqueous core surrounded by a complex, very fluid and adaptable lipid bilayer. In its basic organization broadly similar to a simple lipid vesicle (also called liposome), an elastic liposome differs from the latter by its more flexible and permeable, “softened” bilayer membrane. An elastic liposome vesicle can consequently change shape readily and easily by adjusting relative concentration of its two components in the bilayer to the local stress experienced by the complex bilayer. This can be observed indirectly by studying stress- or deformation-dependent vesicle bilayer elasticity or permeability. In a single experiment, the same goal can be achieved by determining the pressure dependency of elastic liposome suspension-flux through a nano-porous filter (with the pores considerably smaller than the average vesicle size). The rate of resulting transport must grow with driving force (head pressure) non-linearly (often sigmoidally) until maximum flow is reached. For an ideal elastic liposome, experiencing no friction in pores, the maximum flow is equivalent to the flux of the suspending liquid measured with a similar trans-filter pressure, and the minimum pressure required to attain good transport is a measure of bilayer flexibility. The observed functional dependency of suspension flux versus pressure can therefore be used to derive bilayer elasticity and flexibility, as well as permeability, based on theoretical description of the underlying enforced transport, viewed as an activated transport process.
- In some embodiments, the delivery formulation described herein includes a carrier that comprises elastic liposomes. In some embodiments, the liposomes can be nanoparticles containing lipid-encapsulated therapeutic agents. The liposomes or nanoparticles are complex, most often vesicular, aggregates. In some embodiments, the liposomes or nanoparticles can be optimized to attain flexible and self-regulating membrane, which makes the vesicle very deformable. These liposomes or nanoparticles can be typically applied on the skin and can be engineered to achieve high drug concentration at or near the site of application, diminish local or systemic adverse side effects, and often increase drug potency. The term “high drug concentration” refers to a local concentration enough to achieve desired therapeutic effects without incur significant side-effect.
- Liposome nanoparticles can be formed by known method in the art. Generally, the method for forming liposome nanoparticles can be thin film dispersion, reverse-phase evaporation, alcohol infusion, extrusion with or without pressure, which are known in the art (see, e.g., Planas M. E.; Gonzalez M. E.; Rodriguez L. et al. Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes. Anesth. Analg 1992. 75(4):615-621; Gregor Cevc, Gabiele Blume, Andreas S, et al. The skin pathway for systemic treatment with patches and lipid based agent carries[J] Advanced Drug Delivery Reviews, 18:349 (1996); Gregor Cevc, et al., Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements Biochimica et Biophysica Acta 1564:21-30 (2002); G. Cevc, et al., Overcoming semi-permeable barriers, such as the skin, with ultradeformable mixed lipid vesicles, Transfersomes® liposomes or mixed lipid micelles. Langmuir, 19:10753-10763 (2003); Gregor Cevc, Lipid vesicles and other colloids as drug carriers on the skin Advanced Drug Delivery Reviews 56:675-711 (2004)).
-
FIGS. 1A and 1B show two preparations of liposome nanoparticles containing docetaxel. - The device described herein can be used for transdermal delivery of an agent or a combination of agents to treat, prevent, or ameliorate a body condition in need of treatment. The method generally includes treating a skin site of delivery with a microdevice described herein, and delivery an agent to the body of a mammal (e.g., a user or patient).
- Skin is an elastic tissue that deforms when a force is applied. An applicator and method is described for applying a microneedle/nanoporation device, including a plurality of microneedles with a gentle impact. The method is used to improve transport of an active agent through skin barrier.
- It is noteworthy that the prior art uses drug coated tip or hollow microneedles to deliver drug through skin. The present subject matter provides for a method that includes, e.g., pre-treating skin by microneedle array to generate a pre-treated area of skin, and applying to the pre-treated area a wet formulation to allow a therapeutic agent (e.g., drug) or a combination of therapeutic agents to transport through skin. The wet formulation can be in the form of lotion, cream, gel patch, ointment or skin patch. In some embodiments, an occlusive layer is applied over the wet formulation to aid in transporting the therapeutic agents through skin.
- In some embodiments, the agent can be included in the microdevice as a coating with or without a carrier. In these embodiments, the agent can be delivered with the microdevice being attached to the site of delivery until a desired quantity or duration of delivery is achieved.
- In some embodiments, the agent can be separate from the microdevice. In these embodiments, the skin site chosen for delivery the agent can be pre-treated with the microdevice. The agent can then be applied to the skin site of delivery to allow the agent to penetrate into the body of a user or patient.
- The body condition can be a medical condition or a cosmetic condition. Representative medical conditions include, but are not limited to, AIDS, breast cancer, melanoma, liver cancer, lung cancer, blood cancer, pituitary tumors, other cancers, flu, infection, blood disease, cardiac disease, back pain, neck pain, body pain, general pain, arthritis, osteoporosis, headache, depression, smoke, alcoholic, overweight and obesity, menopause, facial hair growth, balding, polycystic ovary syndrome, need of inoculation, need of anesthetics and in particular dermal disease. Representative cosmetic conditions include, but are not limited to, skin aging, skin wrinkle, dark spot, skin discoloration, moisturizing, skin lightening, skin whitening, skin firming, skin lifting, acne, wart, infection, irritation, dry skin and oily skin.
- The present microdevices are designed as disposable or re-usable devices. In one embodiment, the microdevices are disposable. Depending on whether the microdevices have coating of active substances on them or not, there are three categories of applications in the delivery of drugs, cosmetic substances and vaccines in the preferred embodiment.
- For delivery of a drug, vaccine or cosmetic substance, in one embodiment, the microdevices can be used to perforate or scratch stratum corneum. They are then removed immediately and a formulation of an active substance such as a lotion, cream, gel patch, ointment or skin patch with the active substance is applied to the microdevice treated area right away. The formulation will stay on the skin for a pre-defined period, providing sustainable controlled release of an agent such as a drug, or a combination of agents.
- Another embodiment is to store the active agents, as defined below, in the substrate and rely on passive diffusion when the microdevice is in touch with skin.
- In yet another embodiment, one can apply the drugs, in the forms of gel, cream, ointment and lotion, or a combination of those forms, to desired treating area on the skin, then treat the skin area with drug using the said microdevice.
- In yet a further embodiment, one can pre-coat microneedle shaft with a composition that contains active substances. The coated microneedles are applied to the skin and stay on the skin for the entire period of treatment. The rate of through skin transport can be measured using in vitro or in vivo methods known in the art.
- In some embodiments, an area of skin can be pre-treated by the microdevice described herein using an applicator. An “applicator device” or “applicator” as used herein refers to a device or object used to generate nanoconduits in the skin. The applicator preferably comprises a driving structure, element, mechanism, and/or means for generating nanoconduits in the skin. The applicator is preferably used in conjunction with a surface, patch, or reservoir comprising an agent to be delivered. The applicator helps to both deliver agent and generate nanoconduits at a single predetermined skin area at a time. Accordingly, in an alternative embodiment, the applicator may simultaneously generate nanoconduits in the skin area and apply a pre-applied agent.
- In some embodiments, the applicator may employ vibration of one or more frequencies to create an impact force to generate the nanoconduits. For example, in one embodiment, the applicator may contain an exchangeable head, connecting to a battery-powered motor with two eccentric wheels, transforming rotation to vibration. The vibration can create an impact to the skin through a plurality of microneedles mounted on top of the exchangeable head. The frequency of vibration depends on rotation speed and mass distribution of the eccentric wheels and can be in the range of about 10 Hz to about 50000 Hz. In some embodiments, the frequency range can be between about 1000 and about 8000 Hz. An ordinary artisan can design and make an applicator accordingly. Some examples of designing an applicator for various uses are described in U.S. Pat. Nos. 390,089; 1,512,981; 1,657,312; 1,683,851; 1,780,757; 1,790,962; 1,900,609; 2,411,196; 4,237,911; 4,979,525; 5,054,149; 5,095,924; 5,215,193; 5,328,682; 5,713,492; 5,738,122; D416,387; 6,092,252; and 6,220,253, the contents of which are incorporated herein by reference in their entirety.
- In some embodiments, the applicator for mechanical skin treatment comprises:
- (a) a housing having a plurality of walls defining an interior space, the interior space having an upper opening permitting selective access to the interior space of the housing, a cover member being removably couplable to the housing such that the cover is for closing the upper opening of the interior space of the housing; and
- (b) a plurality of microneedle head portion connected to a base portion being removably insertable into the interior space of the housing, each of the applicators being adapted for aiding a user to treat skin;
- wherein the plurality of the applicator including a microneedle array assembly comprising:
-
- (i) the microneedle array assembly being adapted for selectively treating skin,
- (ii) the microneedle assembly having a head portion and a base portion, the head portion being selectively couplable to the base portion such that the base portion is insertable into the interior space of the housing, the base portion of the microneedle array assembly having a pair of depressions, each of the depressions extending along a portion of a length of the base portion, one of the depressions being positioned opposite the other of the depressions such that the depressions are adapted for receiving finger tips of a hand of the user for inhibiting slipping of the base portion from the hand of the user of the applicator.
- In some embodiments, the base portion of the applicator described above can further comprises a motor assembly being positioned in the base portion, the head portion having a drive assembly being positioned in the head portion, the drive assembly being operationally coupled to a base portion, the base portion outwardly extending from an upper end of the head portion, the motor assembly being operationally coupled to the drive assembly such that the motor assembly is for actuating the drive assembly, the drive assembly being for oscillating the base portion when the drive assembly is actuated by the motor assembly.
- In some embodiments, the applicator described above can further comprise a head portion having a plurality of microneedles extending from the base portion, the microneedles being adapted for treat the skin when the microneedle head portion is oscillated by the drive assembly.
- In some embodiments, the applicator described above can further comprise a motor assembly having a motor, the motor having a shaft extending from the motor, the motor being for actuating the shaft, the shaft being for operationally coupling to the drive assembly of the base and head portions such that actuation of the shaft actuates the drive assembly, a power source being operationally coupled to the motor such that the power supply is for providing power to the motor.
- In some embodiments, the applicator described above can include a heavy eccentric mass designed to produce vibration upon actuation of the motor, wherein the motor is actuated to bring the base and head portions into vibration so that skin treatment is practiced through the aid of the vibration, the microneedle application method comprising the steps of:
- predetermining respective weights of the electric applicator and the heavy eccentric mass as well as an eccentric location of the center of gravity of the heavy eccentric mass; establishing an output of the motor at about 1000-15000 rpm in accordance with the predetermined conditions; producing a vibration of about 1000-15000 rpm by actuating the motor;
- conducting the vibration to tips of microneedle on the head portion to increase a pressing force acting along an axial direction of the base and head portion by the use of a minute circular ring connecting to the handle part and pressing against skin area need treatment.
- In some embodiments, the applicator described above can further include a motor assembly having a switch, the switch being operationally coupled between the power supply and the motor, the switch being for controlling power from the power supply to the motor.
- In another aspect, the present subject matter relates to a kit for delivering an agent to a mammal, comprising:
-
- (a) a microdevice comprising a structure selected from microneedles, microblades, microknives, and combinations thereof;
- (b) a wet formulation comprising a bioactive agent;
- (c) an occlusive layer; and
- (d) a mechanism to provide for a driving force sufficient to form nanoconduits on the skin, lined with tissue displaced by the driving force.
- In this regard, the driving force can be, but is not limited to, ultrasound, iontophoresis, radio frequency, laser light, heat gradient, or a combination thereof.
- In addition, the present kits may further comprises an applicator of the microdevice for applying the microdevice to an area of skin of a mammal; and/or a driving force mechanism for driving the bioactive agent to transport through the stratum corneum of the area of skin into the mammal. The driving force mechanism can comprise ultrasound, radio frequency, heat gradient, laser light, iontophoresis device, or a combination thereof. In a preferred embodiment, the applicator is a mechanical applicator.
- The present kits are particularly useful in treating a mammal having a medical condition. Some potential medical conditions treatable by the present kits include, but are not limited to, chronic back pain, a cancer, pre-surgery pain management, operation room pain management, cancer pain, post-surgery pain and lower back pain, and post-surgery pain management.
- In this regard, the agent used in the kits can be, but is not limited to, a natural or synthetic vaccine selected from the group consisting of proteins, peptides, paclitaxel, docetaxel, vaccines, protein vaccines, peptide vaccines, gene vaccines, DNA vaccines, and combinations thereof. Further, the vaccine can be against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, Haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS, and/or cholera. In the alternative, the agent is a pain relieving agent. In this regard, the pain relieving agent can be lidocaine, tetracaine, dyclonine, or a combination of thereof.
- The formulation used in the present kits can comprise elastic liposomes encapsulating the agent. The elastic liposomes can optionally comprise deformable nanoparticles. In the alternative, the formulation in the present kits does not comprises elastic liposomes. In addition, the formulation can be a topical or systemic delivery formulation selected from a skin patch, cream, ointment, or lotion. In a preferred embodiment, the formulation is a wet skin patch.
- In one aspect, active agents or active substances that can be delivered using microdevices are therapeutic agents. The term “therapeutic agent” is used here to refer to active agent that can treat, prevent, and ameliorate a body condition or skin condition that needs treatment. A list of examples includes: drugs, vaccines, peptides, proteins, genes, DNAs, nutraceuticals and cosmetics. The drugs can be administered topically or systemically. Examples of the drugs as active agents include, but not limited to antibiotics, hormones, steroids, anti-inflammatory drugs, protein drugs, DNA drugs whether natural or synthesized, such as Recombinant Erythropoietin (rhEPO), Taxol®, Interferon-alpha-1b, Interferon beta, Interferon gamma, Emla®, Fluorouracil, Lidocaine, Salicylic acid, Pureriran, eflornithine hydrochloride, spironolactone, flutamide, insulin, nanoparticle drugs, Epidural, recombinant human parathyroid hormone, growth hormone, thyroid, cortisol, estrogen, progesterone, and testosterone. Examples of vaccines active agents include, but not limited to: vaccine against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, Haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS and cholera. More examples of cosmetic substances as active agents include, but not limited to: botllinum toxin type A, hyaluronic acid and its derivatives, acetyl hexapeptide-3, vitamin A, vitamin C, vitamin E, alpha-hydroxyacids, collagen and hormones. Diagnostic reagents are also included. Examples include, but not limited to, quantum dots, functionalized nanoparticles, magnetic particles for diagnostic purpose.
- The dosage of the agent can vary according to the medical conditions. The effective amount of an agent that has been well established in the art can be publicly available. Such information can be obtained from the U.S. Food and Drug Administration (FDA), e.g., FDA website. For example, LidoDerm® publishes this type of information.
- In some embodiments, the agent is a pain relieving drug for neuropathic or nociceptive pain management. Such pain relieving drug includes, but is not limited to, Lidocaine; Prilocaine, Tetracaine, Ibuprofen; Acetaminophen; Capsaicin; EMLA®; Tramadol (Ultram); Gabapentin, Tramadol hydrochloride, Corticosteroids, Sufentanil, Clonidine, Bupivacaine, Tricyclic antidepressants, opioid analgesics such as morphine, Hydromorphone, naloxone (Narcan), Talwin, Nubain, Stadol, Fentanyl, Meperidine, Hydrocodone, Codeine, Oxycodone; non-selective NSAIDs such as Celecoxib (Celebrex), rofecoxib (Vioxx), valdecoxib (Bextra); or combinations thereof. In some embodiments, the pain relieving drug described herein can specifically include any of the drug/agents listed herein.
- In some embodiment, the active agent can be muscle relaxants, which include, but are but not limited to, Benzodiazepines; Methocarbamol; Carisoprodol; Chlorzoxazone; Metaxalone; Cyclobenzaprine, or combinations thereof. In some embodiments, the muscle relaxants described herein can specifically exclude any of the drug/agents listed herein.
- In one aspect, the present subject matter provides a
device 10 for delivery of therapeutic active agent as defined above across the skin barrier, stratum corneum layer. Once the substances pass the stratum corneum, there is less resistance for the substances to diffuse into the subsequent layers of the skin: epidermis and dermis. The substances will be absorbed by micro blood vessels and lymphatics in the dermis layer and delivered to entire human body. Microdevices disclosed in the current subject matter can enhance through skin penetration of molecules of molecular weight lower than 500 Dalton. In some embodiments, microdevices can also enable through skin transport of large molecules of molecular weight higher than 500 Dalton. The molecular weight of Bovine Serum Albumin is 66,000 Dalton. The molecular weight of Botulinum Toxin Type A is 150,000 Dalton and the molecular weight of Interferon-Alpha-1b is 17,000 Dalton. - In this regard, the present systems permit the agent to permeate the skin at least 10 times faster than in a system where the formulation is applied to an area of skin which does not contain any generated nanoconduits. In this regard, the agent can permeate the skin to cumulative amounts at least 10 times higher than in a system where the formulation is applied to an area of skin which does not contain any generated nanoconduits.
- In some embodiments, the drug delivery of the present subject matter can be achieved by preparing an area of skin to generate a prepared area of skin and then applying an agent or drug to the prepared area of skin to allow a pre-defined amount of the drug or agent to pass through the stratum corneum of the prepared area of skin.
- In some embodiments, the prepared area of skin can be prepared using a device, e.g., a spring-powered mechanical applicator to apply microneedles to an area of skin. The mechanical applicator can be any structure or design and can cause a mechanical force to be applied to the microneedle against the area of skin to generate pores or channels in the stratum corneum in the area of skin in a pre-defined size and depth. The size and depth of the pores or channels can facilitate the release of controlled amount of an agent or drug through skin.
- In some embodiments, the prepared area of skin can be further treated using an ultrasound device or a mechanical vibrator to apply microneedles to an area of skin. The ultrasound device or mechanical vibrator can cause a pre-set mechanical force to be applied to the microneedle against the area of skin to generate pores or channels in the stratum corneum in the area of skin in a pre-determined size and depth. The size and depth of the pores or channels can provide for controlling the amount of an agent or drug of delivery. It is noteworthy that the ultrasound device or mechanical vibrator can be an effective way to perforate an elastic skin tissue to generate pores or channels in a pre-defined size and/or depth.
- In some embodiments, the prepared area of skin can be prepared in a pre-defined size or dimension (e.g., a dimension of 1 cm.times.1 cm) using an array of microknives or microblades by slicing or lacerating the stratum corneum in an area of skin to generate nanochannels in a pre-defined depth and/or dimension. The dimension and/or depth of the laceration and the dimension of the prepared area of skin can provide for controlling the amount of an agent or drug.
- Allowing an agent or drug to pass through the stratum corneum of a prepared area of skin can be achieved by a variety of mechanisms. For example, the allowing can be achieved by diffusion of the agent or drug from a topical composition (e.g., a formulation such as lotion, cream, gel patch, ointment or skin patch) into the body of a patient or user via the prepared area of skin. In some embodiments, the allowing can be achieved by a driving mechanism, for example, iontophoresis, sonophoresis, radiofrequency (RF) or heat or a combination of these to actively drive agents through the skin.
- Iontophoresis, sonophoresis, radiofrequency (RF) or heat are well developed mechanisms for promoting or enhancing drug delivery. Some examples of iontophoresis systems in drug delivery are described in websites online. Some examples of sonophoresis systems in drug delivery are described in Becker B, Helfrich S, Baker E, et al. Ultrasound with topical anesthetic rapidly decreases pain of intravenous cannulation. Academic Emergency Medicine 2005; 12:289-295; Katz N, Shapiro D, Herrmann T, et al., Rapid onset of cutaneous anesthesia with EMLA cream after pretreatment with a new ultrasound-emitting device. Pain Trials Center, Brigham and Women's Hospital, Boston, Mass.; Mitragotri S, Kost J, Low frequency sonophoresis: A Review. Advanced Drug Delivery Reviews 2004; 56:589-601.
- It is known to one in the art that certain substances have specific functions as cosmetics. For example, Botulinum Toxin Type A is a toxin that blocks neuromuscular transmission when it is injected in small amounts (e.g., 10 units per 0.1 ml injection volume) into specific muscles to treat and reduce wrinkles on the face. The maximum dosage recommended as a single injection for any one muscle at any spot is 25 units. If overdosed or the injection is incorrectly performed, the patient can be left with an immobile face or droopy eyelids till the effect of the injection wears off. The side effects include numbness, swelling and headaches. Administered through microdevices disclosed in the current subject matter, it is possible to provide a controlled release of Botulinum Toxin Type A and keep an optimal local concentration to achieve the best result while minimizing the side effects. In a preferred embodiment of this subject matter, gel patch with botulinum toxin type A is applied to the skin pre-treated with microneedle array. No through skin transport was observed without application of microdevices while significant through skin transport of botulinum toxin type A was observed using the said microdevice. More examples were provided in the above “active agents” section.
- Transdermal delivery of an agent through skin treated by the microdevice described herein has less dependency on molecular weight of the agent. Using the methods described herein, practically, any cosmetic substances can be delivered using microdevices herein. Local concentration can be adjusted through loading and composition for controlled release, as well as a combination of microneedle height, density, size and shape. In one embodiment of this subject matter, one can deliver hyaluronic acid gel through diffusion enhanced by microdevices. Hyaluronic acid is a substance that exists naturally in the body. A major important function of hyaluronic acid is to carry and bind water molecules. Stabilized non-animal hyaluronic acid does not contain animal protein and does not require a skin test prior to treatment. It is thus a preferred embodiment of this subject matter to use microdevices to delivery locally stabilized non-animal hyaluronic acid to treat wrinkles and facial lines.
- Yet, in a further embodiment of this subject matter, one can locally delivery collagen by microneedles, e.g., for allergic skin test and controlled release of collagen into the skin.
- Yet, another embodiment of this subject matter is to provide for local delivery of acetyl hexapeptide-3. This molecule is a non-toxic, non-irritant compound that modulates the excessive stimulation of the facial muscles, relaxing facial tension and it can reduce and prevent the formation of new wrinkles due to over-stimulation of facial muscles. More examples include but not limited to: vitamin A, vitamin C, vitamin E, alpha-hydroxyacids, hormones, or combinations thereof.
- In some embodiments, the microdevice provided herein can be used for topical or systemic delivery of vaccines below the stratum corneum layer. The type of vaccines includes conventional vaccines as well as protein, peptide, DNA vaccines and the like as previously described. Vaccination can be performed by treating a skin site with the microdevice and then delivering a vaccine composition to a user.
- In some embodiments, the microdevice provided herein can be used for topical or systemic delivery of drug with large molecules. The drug can be a protein or peptide. In some embodiments, the drug can be a chemical drug with a relatively high molecular weight. As used herein, the term large molecule refers to a drug having a molecular weight higher than about 300 Daltons. For example, the molecule can have molecular weight higher than about 500 Daltons, higher than about 1000 Daltons, higher than about 5,000 Daltons, higher than about 10,000 Daltons, higher than about 20,000 Daltons, higher than about 50,000 Daltons, higher than about 100,000 Daltons, higher than about 200,000 Daltons, higher than about 500,000 Daltons, or higher than about 1,000,000 Daltons.
- In some embodiments, the drug can be paclitaxel, docetaxel, insulin, Recombinant Erythropoietin (rhEPO), Interferon-alpha, Interferon beta, Interferon gamma, nanoparticle drugs, recombinant human parathyroid hormone, growth hormone, thyroid, cortisol, estrogen, progesterone, and testosterone. Examples of vaccines active agents include, but not limited to: vaccine against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, Haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS and cholera. Examples of cosmetic substances as active agents include, but not limited to: botulinum toxin type A, hyaluronic acid and its derivatives, acetyl hexapeptide-3, vitamin A, vitamin C, vitamin E, alpha-hydroxyacids, collagen and hormones. Diagnostic reagents are also included. Examples include, but not limited to, quantum dots, functionalized nanoparticles, magnetic particles for diagnostic purpose.
- In some embodiments, the microdevice described herein can be used for pain management. The microdevice can be used to facilitate transdermal delivery of a pain relieving agent or a combination of them so as to treat, reduce or prevent pain. In some embodiments, a skin site can be treated with the microdevice and then a pain relieving agent or drug composition can be applied to the treated site, allowing transdermal delivery of these agents to a user.
- The pain relieving agent can be any pain relieving agent approved by FDA or used in medical practice elsewhere in the world. In some embodiments, the pain relieving drug can be, but are not limited to, NSAIDs, COX-2 inhibitors, steroids, muscle relaxants. Specifically, such as Lidocaine; Prilocaine, Tetracaine, Ibuprofen; Acetaminophen; Capsaicin; EMLA®; Tramadol (Ultram); Gabapentin, Tramadol hydrochloride, Corticosteroids, Sufentanil, Clonidine, Bupivacaine, Tricyclic antidepressants, opioid analgesics such as morphine, Hydromorphone, naloxone (Narcan), Talwin, Nubain, Stadol, Fentanyl, Meperidine, Hydrocodone, Codeine, Oxycodone; non-selective NSAIDs such as Celecoxib (Celebrex), rofecoxib (Vioxx), valdecoxib (Bextra); or combinations thereof. In some embodiments, the pain relieving drug described herein can specifically exclude any of the drug/agents listed herein.
- The pain management can be carried out according to a management regime prescribed by a treating doctor. For example, in some embodiment, the pain management is chronic or acute pain management. The pain management regime can be but not limited to, lower back pain, post-herpetic neuralgia, cancer pain, diabetic neuropathy, phantom limb pain, spinal stenosis/sciatica, spinal mets, HIV pain, post-surgery pain, pre-surgery preparation, operation room pain management, pain caused invasive medical procedures such as needle injection, cannulation.
- Different from prior art, the current subject matter involves topical or systemic delivery of pain relieve agent to deep tissues through assistance of a combination of active transdermal delivery methods such as sonophoresis, iontophoresis, laser ablation, radio frequency or heat treatment after the startum corneum are treated with the said microdevices.
- In another aspect, the present systems and methods are useful for treating cancer.
- The microdevices herein preferably deliver drug molecules through skin at a rate that is sufficient to maintain a therapeutic useful concentration in plasma. The size, density, shape and length of the microdevices can be adjusted to meet the delivery requirement. The microdevices can be further coated with a composition that contains active therapeutic molecules, or vaccines, or cosmetic substances, together with polymer binders such as chitosan, carbopol 934P, cellulose and starch to form a dry film. Additional additives of binders, rheology modifiers, surface active agents, stabilizer, rehydration agents may be used. The special composition can control the dissolve rate of the active drug molecule and regulate the drug release rate. The microdevices may be integrated with embedded microfluidic channels that connect to microreservoirs.
- In this regard, the present the methods result in a plateau plasma concentration of agent, wherein the plateau is preferably maintained within 80% of the peak concentration from 10 hours after first contact and up to at least 24 hours after first contact. The plateau can be maintained within 80% of the peak concentration from 10 hours after first contact and up to at least 48 hours after first contact.
- Accordingly, the agents herein have a “drug permeation”, meaning as the amount of agent (mg, or mmol) diffused across the skin barrier within a defined time.
- In some embodiments, the method of delivering an agent, or a combination of agents may include applying an occlusive layer. The occlusive layer may be applied over the applied agent and directly on the prepared area of skin, or the area of skin, such that the occlusive layer prevents air from coming into contact with the prepared area of skin following the removal of the applicator and microdevice from the skin. The occlusive layer is advantageous for preventing evaporation of the agent or combination of agents, and most importantly, allows for increased penetration of an active agent across the skin. The occlusive layer is useful for preventing evaporation of the wet formulation and provides increased penetration of the active agent across the skin.
- In some embodiments, an occlusive layer is applied directly on the prepared area of the skin such that the occlusive layer prevents air from coming into contact with the prepared area of skin following the removal of the applicator and microdevice. The prepared area of skin is generated by applying the applicator to an area of the skin, and subsequently, the occlusive layer is applied directly on the abraded area of skin, either with or without a wet formulation. The occlusive layer may be placed directly on the prepared area of skin to prevent air or other fluids from entering the abraded skin area, other than the et formulation comprising the agent. In some embodiments, in order to prevent air from contacting the prepared area of skin, the occlusive layer must contact the entire abraded area.
- Applying the occlusive layer after applying a wet formulation comprising the agent to the prepared area of skin after the microdevice has generated the plurality of nanopores or nanochannels in the prepared area of skin substantially increases the rate of penetration of the agent. In fact, as described in more detail below,
FIG. 2 shows the difference for drug delivery between occlusive and non-occlusive treatment following microneedle pre-treatment. From the data shown inFIG. 2 , it is clearly evident that applying an occlusive layer after microneedle pre-treatment significantly improves drug delivery since the rate of penetration increases. When compared to non-occlusive treatment after microneedle pre-treatment, or even non-occlusive pretreatment with no microneedle pre-treatment, the rate of penetration is substantially less. In fact, the drug delivery data shown inFIG. 3 shows that the present method unexpectedly provides 72 hours of extended drug release. - In this regard, the data from the graph shown in
FIG. 2 is provided in the Table 1, which shows the effect of the occlusive layer on penetration. -
TABLE 1 Non- Non- Occlusively occlusively Occlusively occlusively with Standard with Standard without Standard without Standard Time(h) microneedles Deviation microneedles Deviation microneedles Deviation microneedles Deviation 2 0.07 0.07 0.08 0.08 0.06 0.09 0.11 0.06 4 1.94 1.41 0.32 0.46 0.18 0.11 0.35 0.30 8 3.74 1.02 1.80 0.91 0.54 0.42 0.54 0.16 12 5.13 1.55 2.60 0.85 0.88 0.49 0.76 0.16 24 10.33 3.43 5.07 1.88 1.71 0.83 1.40 0.22 - The data in Table 1 shows comparative data of the percent penetration of an active agent (docetaxel) in elastic liposomes across skin under four different sets of conditions, where the active is applied to the skin with or without microneedle preparation of skin or use of an occlusive layer:
- (1) yes microneedle, yes occlusive layer;
- (2) yes microneedle, no occlusive layer;
- (3) no microneedle, yes occlusive layer; and
- (4) no microneedle, no occlusive layer.
- The data in Table 1 shows that adding an occlusive layer does not change the percent penetration over 24 hours of the agent across skin not prepared with microneedles. The two data sets (“occlusively without microneedles” vs. “non-occlusively without microneedles”) show statistically the same amount of penetration. In other words, the evidence shows that adding an occlusive layer does not increase the penetration of the agent across unprepared skin.
- Further,
FIG. 2 shows that adding an occlusive layer to skin prepared with microneedles unexpectedly and significantly increases the percent penetration of the active across the prepared skin. This unexpected increase in penetration is due to the combination of the presence of microneedle prepared skin and adding an occlusive layer to the microneedle prepared skin. -
FIG. 6 shows a graph of Trans-Epidermal Water Loss with or without microneedle application. In the graph, the X-axis represents the time in seconds and the Y-axis represents the Trans-Epidermal Water Loss (TEWL). The diamond shaped data points represent the TEWL baseline, and the square shaped data points represent the increase of TEWL after the treatment with the present microdevice. The curve of the square shaped data points decreases over time and eventually merges with the diamond shaped data points at about 200 seconds. This indicates that the skin barrier was initially compromised and penetrated by the microdevice and the skin quickly recovers in about 120-200 seconds or 20-30 minutes. -
FIG. 7 shows a graph of serum insulation concentration with an occlusive layer applied. In particular, the graph shows the prolife of Novolin R® serum insulin concentration vs. time in a diabetic rat after the administration of insulin by the present microdevice. The serum concentration reached 110±5.37 μIU/ml and stayed relatively constant at this level when the occlusive layer was applied. This indicates that the delivery channels were kept open to meet the basal insulin delivery need. The serum concentration rapidly dropped after the removal of the occlusive layer, indicating that the pores closed and the insulin delivery source was cut off. - Before the filing of this application, it was generally considered that the skin barrier rapidly restores resulting in a shorter period of drug delivery. For example, Yang et al., “Topical stratum corneum lipids accelerate barrier repair after tape stripping, solvent treatment and some but not all types of detergent treatment”, Br. J. Dermatol, 1995 November; 133(5):679-85 (hereinafter “Yang”) and Bashir et al., “Physical and physiological effects of stratum corneum tape stripping”, Skin Res. Technol. 2001 February; 7(1):40-8 (hereinafter “Bashir”), teach various means of disrupting the barrier function of the strateum corneum (SC) have been extensively described, including tape-stripping and acetone treatment. Specifically, tape stripping removes the SC mechanically, while acetone treatment extracts lipids from the SC. Restoration of barrier function occurs in a similar amount of time following tape stripping and acetone treatment. Notwithstanding the type of method for penetrating the skin, the pores of the skin generally stay open for a very short period of time providing a limited window for drug delivery. The present microdevice and method overcomes these deficiencies. The present subject matter significantly improves drug delivery since the rate of penetration increases and allows extended drug delivery, i.e., 72 hours as shown in
FIG. 3 . - It is another aspect of the subject matter to provide a device in which clinical biosensor and/or sensor arrays are fabricated in the close vicinity of these HARMS structures. For example, microneedle can collect an extremely low sample volume of body fluids from a patient and allow rapid point-of-care analysis of body fluids. In one embodiment, the sample volume extracted is below 0.1 microliter, typically around 0.01 microliter.
- The HARMS were fabricated using MEMS (Micro-Electro-Mechanical Systems) microfabrication technology. The typical fabrication process involved lithography, wet etch and dry etch, thin film deposition and growth, electroplating, as well as injection molding and hot embossing. One example of fabrication method was to use Bosch process that allowed deep Si etch. It formed HARMS suitable either as device body or mold for further processing. The aspect ratio was higher than 5:1, independent to feature size and pattern shape as long as the features can be defined by lithography. Another fabrication method was KOH or TMAH wet etch of single crystal Si substrate that is <100> orientation or <110> orientation. Yet another fabrication method was using HF solution to electrochemically form porous Si structures. Metals was used for the fabrication of HARMS through a maskless process called electropolishing starting from a structure fabricated by traditional machining methods such as cutting, electro-discharge machining, milling, grinding, polishing and drilling. Use of any single method herein or a combination of these methods as further disclosed in the examples below led to the form of desired HARMS disclosed in the current subject matter.
-
FIGS. 2 and 3 showed the efficacy of transdermal delivery of agents of the present subject matter. In the test shown inFIGS. 2 and 3 , an area of skin was pre-treated with the microneedles described above. Then a formulation of a fluorescence labeled albumin (molecular weight is 66,000) was applied and successfully transport them through skin (FIG. 3 ). The pore formed by the microneedles will not completely be closed within 72 hours after application of the microneedles.FIG. 2 shows Penetration (%) of docetaxel in elastic liposomes with or without microneedle. -
FIG. 4 shows delivery of interferon via different methods. The effectiveness of various delivery methods was assessed by measurement of interferon activity: (a) microneedle with a wet interferon gel on the microneedles, (b) microneedle with a wet interferon gel patch on skin pre-treated with microneedles, (c) subcutaneous injection, and (d) wet interferon gel without microneedle as control sample. -
FIG. 5 shows delivery of interferon with a dry formulation. AsFIG. 5 shows, when the patch is dried, the delivery rate dropped dramatically. - In sum,
FIGS. 4 and 5 show that delivery of interferon using a dry patch is less effective as it is using a wet patch. - While particular embodiments of the present subject matter have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this subject matter in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this subject matter.
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/735,160 US20200179668A1 (en) | 2006-12-22 | 2020-01-06 | Microdevice and method for transdermal delivery and sampling of active substances |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87694806P | 2006-12-22 | 2006-12-22 | |
US11/961,816 US20080214987A1 (en) | 2006-12-22 | 2007-12-20 | Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances |
US15/714,628 US10525246B2 (en) | 2006-12-22 | 2017-09-25 | Microdevice and method for transdermal delivery and sampling of active substances |
US16/735,160 US20200179668A1 (en) | 2006-12-22 | 2020-01-06 | Microdevice and method for transdermal delivery and sampling of active substances |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/714,628 Division US10525246B2 (en) | 2006-12-22 | 2017-09-25 | Microdevice and method for transdermal delivery and sampling of active substances |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200179668A1 true US20200179668A1 (en) | 2020-06-11 |
Family
ID=60989868
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/714,628 Active US10525246B2 (en) | 2006-12-22 | 2017-09-25 | Microdevice and method for transdermal delivery and sampling of active substances |
US16/735,160 Pending US20200179668A1 (en) | 2006-12-22 | 2020-01-06 | Microdevice and method for transdermal delivery and sampling of active substances |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/714,628 Active US10525246B2 (en) | 2006-12-22 | 2017-09-25 | Microdevice and method for transdermal delivery and sampling of active substances |
Country Status (1)
Country | Link |
---|---|
US (2) | US10525246B2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11877848B2 (en) | 2021-11-08 | 2024-01-23 | Satio, Inc. | Dermal patch for collecting a physiological sample |
US11964121B2 (en) | 2021-10-13 | 2024-04-23 | Satio, Inc. | Mono dose dermal patch for pharmaceutical delivery |
US11452474B1 (en) | 2021-04-14 | 2022-09-27 | Satio, Inc. | Dual lever dermal patch system |
US12023156B2 (en) | 2021-10-13 | 2024-07-02 | Satio, Inc. | Dermal patch for collecting a physiological sample |
US11510602B1 (en) | 2021-11-08 | 2022-11-29 | Satio, Inc. | Dermal patch for collecting a physiological sample |
CN114948852B (en) * | 2022-05-26 | 2024-05-17 | 深圳先进技术研究院 | Microneedle system for brain disease diagnosis and treatment and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020147466A1 (en) * | 2001-04-06 | 2002-10-10 | Bernabei Gian Franco | Method and apparatus for skin absorption enhancement and cellulite reduction |
US20030083645A1 (en) * | 2001-10-26 | 2003-05-01 | Massachusetts Institute Of Technology | Microneedle transport device |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3221740A (en) | 1962-08-31 | 1965-12-07 | Rosenthal Sol Roy | Injection device |
US3675766A (en) | 1970-02-04 | 1972-07-11 | Sol Roy Rosenthal | Multiple puncture injector device |
US3964482A (en) | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
US4159659A (en) | 1978-05-16 | 1979-07-03 | Carol Nightingale | Electrical marking device |
US4222392A (en) | 1979-05-23 | 1980-09-16 | Alier-Screen, Inc. | Allergy testing device with vented base |
US4286599A (en) | 1979-01-12 | 1981-09-01 | Geo. A. Hormel & Company | Marking device |
US4381963A (en) | 1980-07-30 | 1983-05-03 | The University Of Rochester | Micro fabrication molding process |
US4340048A (en) | 1981-03-28 | 1982-07-20 | Alza Corporation | Self-driven hypodermic injector |
US4650484A (en) * | 1983-02-03 | 1987-03-17 | Alza Corporation | Method for treating ischemic conditions |
IE53703B1 (en) | 1982-12-13 | 1989-01-18 | Elan Corp Plc | Drug delivery device |
US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
US4938759A (en) | 1986-09-02 | 1990-07-03 | Alza Corporation | Transdermal delivery device having a rate controlling adhesive |
US5139029A (en) | 1990-04-06 | 1992-08-18 | Henry Fishman | Allergy testing apparatus and method |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5156591A (en) | 1990-12-13 | 1992-10-20 | S. I. Scientific Innovations Ltd. | Skin electrode construction and transdermal drug delivery device utilizing same |
US5401242A (en) | 1993-02-25 | 1995-03-28 | Yacowitz; Harold | Apparatus for injecting a substance into the skin |
US5330452A (en) | 1993-06-01 | 1994-07-19 | Zook Gerald P | Topical medicating device |
KR0134152B1 (en) | 1994-05-23 | 1998-04-14 | 이형도 | Skin treatment device for medication |
US5591139A (en) | 1994-06-06 | 1997-01-07 | The Regents Of The University Of California | IC-processed microneedles |
WO1996037155A1 (en) | 1995-05-22 | 1996-11-28 | Silicon Microdevices, Inc. | Micromechanical device and method for enhancing delivery of compounds through the skin |
US5801057A (en) | 1996-03-22 | 1998-09-01 | Smart; Wilson H. | Microsampling device and method of construction |
US5928207A (en) | 1997-06-30 | 1999-07-27 | The Regents Of The University Of California | Microneedle with isotropically etched tip, and method of fabricating such a device |
DE69806963T2 (en) | 1997-12-11 | 2002-11-21 | Alza Corp | DEVICE FOR INCREASING THE TRANSDERMAL ACTIVE SUBSTANCE FLOW |
CA2330207C (en) | 1998-06-10 | 2005-08-30 | Georgia Tech Research Corporation | Microneedle devices and methods of manufacture and use thereof |
US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
GB9815819D0 (en) | 1998-07-22 | 1998-09-16 | Secr Defence | Transferring materials into cells and a microneedle array |
GB9815820D0 (en) | 1998-07-22 | 1998-09-16 | Secr Defence | Improvements relating to micro-machining |
US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
US6312612B1 (en) | 1999-06-09 | 2001-11-06 | The Procter & Gamble Company | Apparatus and method for manufacturing an intracutaneous microneedle array |
US6623457B1 (en) | 1999-09-22 | 2003-09-23 | Becton, Dickinson And Company | Method and apparatus for the transdermal administration of a substance |
US6835184B1 (en) | 1999-09-24 | 2004-12-28 | Becton, Dickinson And Company | Method and device for abrading skin |
US8465468B1 (en) | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
US20020095134A1 (en) | 1999-10-14 | 2002-07-18 | Pettis Ronald J. | Method for altering drug pharmacokinetics based on medical delivery platform |
US6511463B1 (en) | 1999-11-18 | 2003-01-28 | Jds Uniphase Corporation | Methods of fabricating microneedle arrays using sacrificial molds |
ES2253278T3 (en) | 1999-12-10 | 2006-06-01 | Alza Corporation | DEVICE AND PROCEDURE FOR IMPROVING CUTANEOUS PERFORATION WITH MICROPROTUBERANCES. |
AU782610B2 (en) | 1999-12-10 | 2005-08-11 | Alza Corporation | Skin treatment apparatus for sustained transdermal drug delivery |
US6558361B1 (en) | 2000-03-09 | 2003-05-06 | Nanopass Ltd. | Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems |
CA2843053C (en) * | 2000-06-01 | 2015-08-25 | Georgetown University | Systems and methods for monitoring health and delivering drugs transdermally |
US6603987B2 (en) | 2000-07-11 | 2003-08-05 | Bayer Corporation | Hollow microneedle patch |
US7850663B2 (en) | 2001-01-12 | 2010-12-14 | Becton, Dickinson And Company | Medicament microdevice delivery system, cartridge and method of use |
US6855372B2 (en) | 2001-03-16 | 2005-02-15 | Alza Corporation | Method and apparatus for coating skin piercing microprojections |
JP2004528900A (en) | 2001-04-20 | 2004-09-24 | アルザ・コーポレーシヨン | Microprojection array with coating containing beneficial agent |
GB0201736D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | DNA dosage forms |
US20040060902A1 (en) | 2002-02-05 | 2004-04-01 | Evans John D. | Microprotrusion array and methods of making a microprotrusion |
US7971220B2 (en) * | 2002-04-30 | 2011-06-28 | Thomson Licensing | System, method, computer program product, and apparatus for automatically ensuring consistency between program and system information protocol tables and program specific information tables in a digital television stream |
US20030225363A1 (en) | 2002-05-28 | 2003-12-04 | Raphael Gordon | Surgical cassette |
US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
US20040092498A1 (en) | 2002-08-16 | 2004-05-13 | David Blakemore | Substituted glycine derivatives for use as medicaments |
US7465661B2 (en) | 2003-05-28 | 2008-12-16 | The United States Of America As Represented By The Secretary Of The Navy | High aspect ratio microelectrode arrays |
EP1643918A1 (en) | 2003-07-02 | 2006-04-12 | Alza Corporation | Microprojection array immunization patch and method |
DK2609946T3 (en) | 2003-08-12 | 2018-08-27 | Becton Dickinson Co | PLASTER-LIKE INFUSION DEVICE WITH PROTECTIVE ELEMENT |
JP2007508914A (en) | 2003-10-24 | 2007-04-12 | アルザ・コーポレーシヨン | Apparatus and method for facilitating transdermal drug delivery |
ES2377647T3 (en) | 2003-10-31 | 2012-03-29 | Alza Corporation | Self-acting applicator for microprojection ordering |
CA2543639A1 (en) | 2003-10-31 | 2005-05-19 | Alza Corporation | System and method for transdermal vaccine delivery |
MXPA06007832A (en) | 2004-01-09 | 2007-01-26 | Johnson & Johnson | Frequency assisted transdermal agent delivery method and system. |
US7591806B2 (en) * | 2004-05-18 | 2009-09-22 | Bai Xu | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
DE102004036957B3 (en) * | 2004-07-30 | 2006-06-14 | Infineon Technologies Ag | Method for generating test signals and use of a test system for carrying out the method |
US7316665B2 (en) * | 2004-08-25 | 2008-01-08 | Becton, Dickinson And Company | Method and device for the delivery of a substance including a covering |
US20060264804A1 (en) | 2005-04-07 | 2006-11-23 | Yoram Karmon | Device and kit for delivery of encapsulated substances and methods of use thereof |
-
2017
- 2017-09-25 US US15/714,628 patent/US10525246B2/en active Active
-
2020
- 2020-01-06 US US16/735,160 patent/US20200179668A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020147466A1 (en) * | 2001-04-06 | 2002-10-10 | Bernabei Gian Franco | Method and apparatus for skin absorption enhancement and cellulite reduction |
US20030083645A1 (en) * | 2001-10-26 | 2003-05-01 | Massachusetts Institute Of Technology | Microneedle transport device |
Also Published As
Publication number | Publication date |
---|---|
US10525246B2 (en) | 2020-01-07 |
US20180021559A1 (en) | 2018-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2099436B1 (en) | Microdevice and method for transdermal delivery and sampling of active substances | |
US20200179668A1 (en) | Microdevice and method for transdermal delivery and sampling of active substances | |
EP2056921B1 (en) | High-aspect-ratio microdevices for transdermal delivery and sampling of active substances | |
US8043250B2 (en) | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances | |
Waghule et al. | Microneedles: A smart approach and increasing potential for transdermal drug delivery system | |
Bhatnagar et al. | Microneedles in the clinic | |
US8048017B2 (en) | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances | |
US7591806B2 (en) | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances | |
Jijie et al. | Nanomaterials for transdermal drug delivery: beyond the state of the art of liposomal structures | |
EP2547396B1 (en) | A built-in non-verbal instructional device integratable to applicators | |
JP2007535337A (en) | Delivery of therapeutic peptide and protein polymer conjugates by coated microprojections | |
G Nava-Arzaluz et al. | Microneedles as transdermal delivery systems: combination with other enhancing strategies | |
Grice et al. | Electrical and physical methods of skin penetration enhancement | |
CN108697639B (en) | Percutaneous absorption composition and application thereof in preparing percutaneous absorption preparation | |
Jain et al. | Transdermal Drug Delivery | |
Bodkhe et al. | A review of microneedles–elevation to TDDS approach and function in management of psoriasis | |
CN214260363U (en) | Nano microneedle | |
JP6028063B2 (en) | Built-in non-verbal instruction device that can be integrated into the applicator | |
US20220265589A1 (en) | Method of administering a dual therapeutic and cosmetic agent | |
Birchall | 18 Stratum Corneum Bypassed or Removed | |
MXPA06004721A (en) | Delivery of polymer conjugates of therapeutic peptides and proteins via coated microporjections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NANOMED SKINCARE, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:XU, BAI;REEL/FRAME:051449/0177 Effective date: 20170921 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |